{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:28:30Z","timestamp":1793172510946,"version":"4.5.0"},"reference-count":820,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1446100"],"award-info":[{"award-number":["24ZR1446100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070358"],"award-info":[{"award-number":["82070358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470433"],"award-info":[{"award-number":["82470433"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770430"],"award-info":[{"award-number":["81770430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2022YFA1105104"],"award-info":[{"award-number":["2022YFA1105104"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.isci.2025.114042","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:51:28Z","timestamp":1763538688000},"page":"114042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders"],"prefix":"10.1016","volume":"28","author":[{"given":"Feifei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114042_bib1","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: A structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.isci.2025.114042_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100406","article-title":"Full-length nuclear receptor allosteric regulation","volume":"64","author":"Choi","year":"2023","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib174","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ctrv.2014.10.005","article-title":"Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers","volume":"40","author":"Roshan-Moniri","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.isci.2025.114042_bib175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear Receptors, RXR, and the Big Bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114042_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121852","article-title":"Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer","volume":"11","author":"Porter","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.114042_bib177","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/bs.pmbts.2022.07.014","article-title":"Nuclear receptor: Structure and function","volume":"196","author":"Sar","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib2","first-page":"S223","article-title":"The Concise Guide to PHARMACOLOGY 2023\/24: Nuclear hormone receptors","volume":"180","author":"Alexander","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beem.2015.07.007","article-title":"Resistance to thyroid hormone due to defective thyroid receptor alpha","volume":"29","author":"Moran","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004911","article-title":"Nongenomic thyroid hormone signaling occurs through a plasma membrane-localized receptor","volume":"7","author":"Kalyanaraman","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2025.114042_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115012","article-title":"Obesity I: Overview and molecular and biochemical mechanisms","volume":"199","author":"Lustig","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1110296","article-title":"A mutation in the thyroid hormone receptor alpha gene","volume":"366","author":"Bochukova","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib7","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/157489011794578473","article-title":"Sobetirome: a selective thyromimetic for the treatment of dyslipidemia","volume":"6","author":"Tancevski","year":"2011","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.isci.2025.114042_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a Novel Thyroid Hormone Receptor-beta Agonist for the Treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934971","article-title":"Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors","volume":"13","author":"Emamnejad","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nrd2397","article-title":"RAR and RXR modulation in cancer and metabolic disease","volume":"6","author":"Altucci","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2025.114042_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166085","article-title":"The role of the retinoid receptor, RAR\/RXR heterodimer, in liver physiology","volume":"1867","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.isci.2025.114042_bib13","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.26699","article-title":"All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade","volume":"59","author":"Kim","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.lfs.2008.02.002","article-title":"PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation","volume":"82","author":"Okayasu","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.isci.2025.114042_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-6980(03)00003-0","article-title":"Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation","volume":"71","author":"Bishop-Bailey","year":"2003","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.isci.2025.114042_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.107.158477","article-title":"Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta","volume":"102","author":"Kim","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib18","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.2337\/db12-0117","article-title":"PPAR\u03b4 activation protects endothelial function in diabetic mice","volume":"61","author":"Tian","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00125-011-2401-4","article-title":"The peroxisome proliferator-activated receptor (PPAR) \u03b2\/\u03b4 agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells","volume":"55","author":"Serrano-Marco","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2025.114042_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib21","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1073\/pnas.0711875105","article-title":"PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis","volume":"105","author":"Barish","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154342","article-title":"Revealing the role of peroxisome proliferator-activated receptor \u03b2\/\u03b4 in nonalcoholic fatty liver disease","volume":"114","author":"Zarei","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114042_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2009.03732.x","article-title":"Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation","volume":"8","author":"Moraes","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.isci.2025.114042_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib27","article-title":"Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.isci.2025.114042_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2024.2401614","article-title":"Pioglitazone as a potential modulator in autoimmune diseases: a review on its effects in systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis","volume":"21","author":"Nasrabadi","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib29","first-page":"682","article-title":"Orphan Nuclear Receptors in Metabolic Dysfunction-associated Steatotic Liver Disease Development","volume":"13","author":"Li","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2015.03.070","article-title":"Suppression of atherosclerosis by synthetic REV-ERB agonist","volume":"460","author":"Sitaula","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/CIRCULATIONAHA.121.057623","article-title":"Nuclear Receptor NR1D1 Regulates Abdominal Aortic Aneurysm Development by Targeting the Mitochondrial Tricarboxylic Acid Cycle Enzyme Aconitase-2","volume":"146","author":"Sun","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.899628","article-title":"REV-ERB is essential in cardiac fibroblasts homeostasis","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib33","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1038\/s41467-024-51716-9","article-title":"Prefrontal cortex molecular clock modulates development of depression-like phenotype and rapid antidepressant response in mice","volume":"15","author":"Sarrazin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/aps.2014.120","article-title":"ROR nuclear receptors: structures, related diseases, and drug discovery","volume":"36","author":"Zhang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2025.114042_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.molmet.2016.07.001","article-title":"Inhibition of ROR\u03b1\/\u03b3 suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation","volume":"5","author":"Billon","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1102469","article-title":"Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases","volume":"10","author":"Griffett","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2025.114042_bib37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","article-title":"Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils","volume":"24","author":"Kirchgessner","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver X receptors in lipid signalling and membrane homeostasis","volume":"14","author":"Wang","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib39","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1172\/JCI66533","article-title":"LXR\u03b2\/estrogen receptor-\u03b1 signaling in lipid rafts preserves endothelial integrity","volume":"123","author":"Ishikawa","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib40","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/ATVBAHA.109.189506","article-title":"Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR\/LXR heterodimer in the liver","volume":"29","author":"Lalloyer","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib41","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1161\/ATVBAHA.125.322448","article-title":"Inhibition of LXR Signaling in Human Foam Cells Impairs Macrophage-to-Endothelial Cell Cross Talk and Promotes Endothelial Cell Inflammation","volume":"45","author":"Leleu","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10409238.2021.1925217","article-title":"Cholesterol efflux pathways, inflammation, and atherosclerosis","volume":"56","author":"Groenen","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.15386\/mpr-2628","article-title":"Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target","volume":"97","author":"Stan","year":"2024","journal-title":"Med. Pharm. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib45","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17460441.2021.1916465","article-title":"The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease","volume":"16","author":"Fiorucci","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.isci.2025.114042_bib46","doi-asserted-by":"crossref","first-page":"18180","DOI":"10.1074\/jbc.RA118.004652","article-title":"Ligand binding and heterodimerization with retinoid X receptor \u03b1 (RXR\u03b1) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding","volume":"293","author":"Wang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib47","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.biotechadv.2018.03.003","article-title":"Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR","volume":"36","author":"Hiebl","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.isci.2025.114042_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048461","article-title":"Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis","volume":"7","author":"Peng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib49","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/ATVBAHA.116.308093","article-title":"Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets","volume":"36","author":"Moraes","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib50","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/er.2004-0002","article-title":"Noncalcemic actions of vitamin D receptor ligands","volume":"26","author":"Nagpal","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/nu14142847","article-title":"Vitamin D and Its Receptor from a Structural Perspective","volume":"14","author":"Rochel","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2025.114042_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/nu14061291","article-title":"Rapid Nontranscriptional Effects of Calcifediol and Calcitriol","volume":"14","author":"Donati","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2025.114042_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10577","article-title":"Integrated View on the Role of Vitamin D Actions on Bone and Growth Plate Homeostasis","volume":"5","author":"Verlinden","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.isci.2025.114042_bib54","article-title":"Vitamin D and Immune Regulation: Antibacterial, Antiviral, Anti-Inflammatory","volume":"5","author":"E","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.isci.2025.114042_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40200-015-0186-6","article-title":"Vitamin D & its analogues in type 2 diabetic nephropathy: a systematic review","volume":"14","author":"Chokhandre","year":"2015","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.isci.2025.114042_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112395","article-title":"Regulation of CAR and PXR Expression in Health and Disease","volume":"9","author":"Daujat-Chavanieu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib57","doi-asserted-by":"crossref","first-page":"G74","DOI":"10.1152\/ajpgi.00258.2004","article-title":"Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription","volume":"288","author":"Li","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53218-x","article-title":"Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis","volume":"9","author":"Flora","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425255.2012.685237","article-title":"Role of CAR and PXR in xenobiotic sensing and metabolism","volume":"8","author":"Wang","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.isci.2025.114042_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apsb.2019.06.012","article-title":"PXR: a center of transcriptional regulation in cancer","volume":"10","author":"Xing","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.isci.2025.114042_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib62","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41467-024-46559-3","article-title":"Diindoles produced from commensal microbiota metabolites function as endogenous CAR\/Nr1i3 ligands","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/acsmedchemlett.9b00079","article-title":"DL5050, a Selective Agonist for the Human Constitutive Androstane Receptor","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.isci.2025.114042_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122532","article-title":"Diazepam Promotes Translocation of Human Constitutive Androstane Receptor (CAR) via Direct Interaction with the Ligand-Binding Domain","volume":"9","author":"Skoda","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13238-013-0013-0","article-title":"Signaling control of the constitutive androstane receptor (CAR)","volume":"5","author":"Yang","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.isci.2025.114042_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hep4.1274","article-title":"Constitutive Androstane Receptor Differentially Regulates Bile Acid Homeostasis in Mouse Models of Intrahepatic Cholestasis","volume":"3","author":"Kim","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib67","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1073\/pnas.0909731106","article-title":"Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease","volume":"106","author":"Dong","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cld.2012.12.001","article-title":"Nuclear receptors as drug targets in cholestatic liver diseases","volume":"17","author":"Halilbasic","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.isci.2025.114042_bib69","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/1471-2164-12-560","article-title":"Nuclear receptor HNF4\u03b1 binding sequences are widespread in Alu repeats","volume":"12","author":"Bolotin","year":"2011","journal-title":"BMC Genom."},{"key":"10.1016\/j.isci.2025.114042_bib70","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.celrep.2019.11.066","article-title":"Molecular Basis for Autosomal-Dominant Renal Fanconi Syndrome Caused by HNF4A","volume":"29","author":"Marchesin","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.114042_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1152\/physiol.00007.2012","article-title":"Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesity","volume":"27","author":"Pearen","year":"2012","journal-title":"Physiology"},{"key":"10.1016\/j.isci.2025.114042_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1232569","article-title":"Multiple roles and regulatory mechanisms of the transcription factor HNF4 in the intestine","volume":"14","author":"Vemuri","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/JOE-21-0092","article-title":"Hnf4g invalidation prevents diet-induced obesity via intestinal lipid malabsorption","volume":"252","author":"Ayari","year":"2021","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1464655","article-title":"Retinoid X receptor heterodimers in hepatic function: structural insights and therapeutic potential","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/intimm\/dxy089","article-title":"A partial agonist for retinoid X receptor mitigates experimental colitis","volume":"31","author":"Onuki","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib76","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1210\/en.2005-0690","article-title":"Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes","volume":"147","author":"Leibowitz","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib77","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","article-title":"Nuclear receptors and lipid physiology: opening the X-files","volume":"294","author":"Chawla","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.114042_bib78","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.bbamcr.2012.06.030","article-title":"Dual function of Pin1 in NR4A nuclear receptor activation: enhanced activity of NR4As and increased Nur77 protein stability","volume":"1823","author":"van Tiel","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2025.114042_bib79","doi-asserted-by":"crossref","first-page":"30625","DOI":"10.1021\/acsomega.0c04623","article-title":"Identification of Small-Molecule Regulators of Testicular Receptor 4 via a Drug Repurposing Screening","volume":"5","author":"Xia","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.isci.2025.114042_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1095\/biolreprod.110.083824","article-title":"Nuclear receptors in Leydig cell gene expression and function","volume":"83","author":"Martin","year":"2010","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.isci.2025.114042_bib81","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1074\/jbc.M110.168740","article-title":"The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/genes15050563","article-title":"Roles of Nuclear Orphan Receptors TR2 and TR4 during Hematopoiesis","volume":"15","author":"Myers","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.isci.2025.114042_bib83","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/bs.ctdb.2017.02.002","article-title":"TR2 and TR4 Orphan Nuclear Receptors: An Overview","volume":"125","author":"Lin","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib84","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023784119","article-title":"Oleic acid is an endogenous ligand of TLX\/NR2E1 that triggers hippocampal neurogenesis","volume":"119","author":"Kandel","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib85","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.chembiol.2020.07.013","article-title":"The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids","volume":"27","author":"Griffett","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12264-015-0004-7","article-title":"The Orphan Nuclear Receptor TLX\/NR2E1 in Neural Stem Cells and Diseases","volume":"32","author":"Wang","year":"2016","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.isci.2025.114042_bib87","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/bs.ctdb.2016.12.003","article-title":"Nuclear Receptor TLX in Development and Diseases","volume":"125","author":"Sun","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib88","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1038\/s41598-022-11502-3","article-title":"Biliverdin regulates NR2E3 and zebrafish retinal photoreceptor development","volume":"12","author":"Connor","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib89","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1167\/iovs.16-20177","article-title":"Potential of Small Molecule-Mediated Reprogramming of Rod Photoreceptors to Treat Retinitis Pigmentosa","volume":"57","author":"Nakamura","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.98","article-title":"Heterodimers of photoreceptor-specific nuclear receptor (PNR\/NR2E3) and peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) are disrupted by retinal disease-associated mutations","volume":"8","author":"Fulton","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2025.114042_bib91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/humu.21096","article-title":"NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP)","volume":"30","author":"Schorderet","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.isci.2025.114042_bib92","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1478-811X-12-38","article-title":"Orphan nuclear receptor NR2F6 acts as an essential gatekeeper of Th17 CD4+ T cell effector functions","volume":"12","author":"Hermann-Kleiter","year":"2014","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2025.114042_bib93","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/bs.ctdb.2016.12.002","article-title":"COUP-TF Genes, Human Diseases, and the Development of the Central Nervous System in Murine Models","volume":"125","author":"Yang","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002273","article-title":"The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36","volume":"7","author":"Zhou","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib95","series-title":"GeneReviews((R))","article-title":"NR2F1-Related Neurodevelopmental Disorder","author":"Schaaf","year":"1993"},{"key":"10.1016\/j.isci.2025.114042_bib96","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajhg.2014.03.007","article-title":"Rare variants in NR2F2 cause congenital heart defects in humans","volume":"94","author":"Al Turki","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.isci.2025.114042_bib97","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/ajmg.a.37830","article-title":"De novo frameshift mutation in COUP-TFII (NR2F2) in human congenital diaphragmatic hernia","volume":"170","author":"High","year":"2016","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.isci.2025.114042_bib98","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1001\/jama.295.23.jed60037","article-title":"Selective estrogen receptor modulators and prevention of invasive breast cancer","volume":"295","author":"Gradishar","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.114042_bib99","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume":"29","author":"Klinge","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2025.114042_bib100","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1091\/mbc.e03-06-0360","article-title":"Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta","volume":"15","author":"Tee","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib101","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endrev\/bnab041","article-title":"Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease","volume":"43","author":"Mauvais-Jarvis","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib102","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCRESAHA.115.305376","article-title":"The Expanding Complexity of Estrogen Receptor Signaling in the Cardiovascular System","volume":"118","author":"Menazza","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib103","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s10787-025-01792-0","article-title":"Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction","volume":"33","author":"Fardoun","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.isci.2025.114042_bib104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/0929867330666230220123237","article-title":"Estrogen Receptor and the Gender Bias in Raynaud's Phenomenon","volume":"31","author":"Fardoun","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/CIRCULATIONAHA.123.066542","article-title":"Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function","volume":"149","author":"Xu","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2024.109500","article-title":"Exploring the impact of estrogen-related receptor gamma on metabolism and disease","volume":"211","author":"Sadasivam","year":"2024","journal-title":"Steroids"},{"key":"10.1016\/j.isci.2025.114042_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041091","article-title":"Emerging Roles of Estrogen-Related Receptors in the Brain: Potential Interactions with Estrogen Signaling","volume":"19","author":"Saito","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s44324-024-00013-6","article-title":"Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease","volume":"2","author":"Antwi","year":"2024","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.isci.2025.114042_bib109","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-022-29733-3","article-title":"The nuclear receptor ERR cooperates with the cardiogenic factor GATA4 to orchestrate cardiomyocyte maturation","volume":"13","author":"Sakamoto","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib110","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1038\/s41467-024-48255-8","article-title":"Targeting adipocyte ESRRA promotes osteogenesis and vascular formation in adipocyte-rich bone marrow","volume":"15","author":"Huang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib111","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.2337\/db12-0946","article-title":"Inverse agonist of nuclear receptor ERR\u03b3 mediates antidiabetic effect through inhibition of hepatic gluconeogenesis","volume":"62","author":"Kim","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib112","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ando.2018.03.004","article-title":"Glucocorticoid receptor modulators","volume":"79","author":"Meijer","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040683","article-title":"Dimerization of the Glucocorticoid Receptor and Its Importance in (Patho)physiology: A Primer. Cells 11","volume":"11","author":"Timmermans","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib114","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-genomic Effects of Glucocorticoids: An Updated View","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib116","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/bph.15746","article-title":"Structural and molecular determinants of mineralocorticoid receptor signalling","volume":"179","author":"Grossmann","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.isci.2025.114042_bib118","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/en.2019-00258","article-title":"PKC\u03b4 Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function","volume":"160","author":"Lu","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists","volume":"54","author":"Mende","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.isci.2025.114042_bib120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mce.2011.07.017","article-title":"Structural and functional analysis of domains of the progesterone receptor","volume":"348","author":"Hill","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/me.2008-0028","article-title":"A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2","volume":"23","author":"Magklara","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib122","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1074\/jbc.M805226200","article-title":"Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation","volume":"284","author":"Abdel-Hafiz","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib123","doi-asserted-by":"crossref","first-page":"E899","DOI":"10.1152\/ajpendo.00527.2014","article-title":"Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-\u03b1","volume":"308","author":"Pang","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib124","doi-asserted-by":"crossref","first-page":"H341","DOI":"10.1152\/ajpheart.00206.2020","article-title":"Progesterone promotes endothelial nitric oxide synthase expression through enhancing nuclear progesterone receptor-SP-1 formation","volume":"319","author":"You","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib125","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","article-title":"Progesterone action in breast, uterine, and ovarian cancers","volume":"54","author":"Diep","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107209","article-title":"The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review","volume":"152","author":"Stone","year":"2023","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acsmedchemlett.5b00377","article-title":"Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs)","volume":"7","author":"Handlon","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.isci.2025.114042_bib128","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.embor.7401046","article-title":"New androgen receptor genomic targets show an interaction with the ETS1 transcription factor","volume":"8","author":"Massie","year":"2007","journal-title":"EMBO Rep."},{"key":"10.1016\/j.isci.2025.114042_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0303-7207(97)00116-0","article-title":"Ubiquitous transcription factors NF1 and Sp1 are involved in the androgen activation of the mouse vas deferens protein promoter","volume":"132","author":"Darne","year":"1997","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib130","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-19-0032","article-title":"Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers","volume":"26","author":"Stelloo","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.isci.2025.114042_bib131","first-page":"183","article-title":"Androgen actions on endothelium functions and cardiovascular diseases","volume":"13","author":"Cai","year":"2016","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1112892","article-title":"The role of androgens in pressure overload myocardial hypertrophy","volume":"14","author":"Schafstedde","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib133","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/JOE-14-0611","article-title":"Androgen receptor in human endothelial cells","volume":"224","author":"Torres-Estay","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib134","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nchembio.106","article-title":"Cytosporone B is an agonist for nuclear orphan receptor Nur77","volume":"4","author":"Zhan","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106156","article-title":"SAR study of oxidative DIMs analogs targeting the Nur77-mediated apoptotic pathway of cancer cells","volume":"129","author":"Chen","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib136","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molcel.2017.03.008","article-title":"Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy","volume":"66","author":"Hu","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib137","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.chembiol.2019.02.002","article-title":"Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite","volume":"26","author":"Bruning","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib138","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41589-020-0553-6","article-title":"PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function","volume":"16","author":"Rajan","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib139","doi-asserted-by":"crossref","first-page":"15639","DOI":"10.1021\/acs.jmedchem.0c00894","article-title":"Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1","volume":"63","author":"Munoz-Tello","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib140","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1248\/bpb.28.1603","article-title":"Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily","volume":"28","author":"Kagaya","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.isci.2025.114042_bib141","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114042_bib142","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/CIRCRESAHA.124.325645","article-title":"NR4A1 Acts as a Novel Regulator of Platelet Activation and Thrombus Formation","volume":"136","author":"Liu","year":"2025","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib143","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s11658-020-00241-w","article-title":"The nuclear receptor 4A family members: mediators in human disease and autophagy","volume":"25","author":"Chen","year":"2020","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.isci.2025.114042_bib144","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MOL.0b013e3283643eac","article-title":"NR4A nuclear receptors in immunity and atherosclerosis","volume":"24","author":"Hamers","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.isci.2025.114042_bib145","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2017.08.053","article-title":"Glycated apolipoprotein A-IV induces atherogenesis in patients with CAD in type 2 diabetes","volume":"70","author":"Dai","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib146","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1161\/CIRCRESAHA.123.323699","article-title":"Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation","volume":"134","author":"Ma","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib147","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tcm.2018.11.015","article-title":"NR4A nuclear receptors in cardiac remodeling and neurohormonal regulation","volume":"29","author":"Medzikovic","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.isci.2025.114042_bib148","doi-asserted-by":"crossref","first-page":"15054","DOI":"10.1073\/pnas.1416740111","article-title":"The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1","volume":"111","author":"Blind","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib149","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1021\/jm060990k","article-title":"Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1","volume":"49","author":"Whitby","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79251-9","article-title":"Enantiomer-specific activities of an LRH-1 and SF-1 dual agonist","volume":"10","author":"Mays","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib151","first-page":"377","article-title":"Consensus sequence of transcription factor SF-1 binding site and putative binding site in the 5' flanking regions of genes encoding mouse steroidogenic enzymes 3betaHSDI and Cyp17","volume":"68","author":"Busygina","year":"2003","journal-title":"Biochemistry."},{"key":"10.1016\/j.isci.2025.114042_bib152","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-1336-1-8","article-title":"SF-1 a key player in the development and differentiation of steroidogenic tissues","volume":"18","author":"Val","year":"2003","journal-title":"Nucl. Recept."},{"key":"10.1016\/j.isci.2025.114042_bib153","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuron.2005.12.021","article-title":"Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis","volume":"49","author":"Dhillon","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.isci.2025.114042_bib154","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/9629","article-title":"A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans","volume":"22","author":"Achermann","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2025.114042_bib155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnins.2013.00071","article-title":"Revisiting the Ventral Medial Nucleus of the Hypothalamus: The Roles of SF-1 Neurons in Energy Homeostasis","volume":"7","author":"Choi","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.isci.2025.114042_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104921","article-title":"Comparison of activity, structure, and dynamics of SF-1 and LRH-1 complexed with small molecule modulators","volume":"299","author":"Cato","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib157","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jsb.2015.09.012","article-title":"Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket","volume":"192","author":"Sablin","year":"2015","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib158","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2164-13-51","article-title":"Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR","volume":"13","author":"Chong","year":"2012","journal-title":"BMC Genom."},{"key":"10.1016\/j.isci.2025.114042_bib159","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bbadis.2010.12.010","article-title":"Emerging actions of the nuclear receptor LRH-1 in the gut","volume":"1812","author":"Fernandez-Marcos","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2025.114042_bib160","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10111","article-title":"A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects","volume":"474","author":"Lee","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114042_bib161","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121905","article-title":"Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis","volume":"11","author":"Landskron","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib162","article-title":"The expanding roles of Nr6a1 in development and evolution","volume":"12","author":"Li","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib163","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.semcdb.2013.08.003","article-title":"Revisiting the role of GCNF in embryonic development","volume":"24","author":"Wang","year":"2013","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib164","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1038\/s41467-025-60574-y","article-title":"Variants in NR6A1 cause a novel oculo vertebral renal syndrome","volume":"16","author":"Neelathi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib165","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1074\/jbc.M109.073650","article-title":"Orphan nuclear receptor DAX-1 acts as a novel corepressor of liver X receptor alpha and inhibits hepatic lipogenesis","volume":"285","author":"Nedumaran","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib166","article-title":"Nuclear receptor Dax1 promotes atherosclerosis by lipid transport inhibition and autophagy suppression in macrophages","author":"Li","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.isci.2025.114042_bib167","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/0008-5472.CAN-06-2164","article-title":"Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor","volume":"67","author":"Farhana","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114042_bib168","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1093\/nar\/gkq227","article-title":"Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation","volume":"38","author":"Chanda","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2025.114042_bib169","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/15548627.2022.2108296","article-title":"Paradoxical feeding activation of gut lipophagy by FGF15\/FGF19-NR0B2\/SHP-TFEB","volume":"19","author":"Seok","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.isci.2025.114042_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166639","article-title":"Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis","volume":"1869","author":"Zhou","year":"2023","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.isci.2025.114042_bib171","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1073\/pnas.98.2.575","article-title":"Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects","volume":"98","author":"Nishigori","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib178","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/thy.2020.0720","article-title":"Evidence-Based Use of Levothyroxine\/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document","volume":"31","author":"Jonklaas","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.isci.2025.114042_bib179","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, \u03b2-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib181","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib182","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3803\/EnM.2024.203","article-title":"Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib183","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2014.09.035","article-title":"The thyroid receptor beta modulator GC-1 reduces atherosclerosis in ApoE deficient mice","volume":"237","author":"Kannisto","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.isci.2025.114042_bib184","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.isci.2025.114042_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a Novel Thyroid Hormone Receptor-\u03b2 Agonist for the Treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib186","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib187","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ijd.12191","article-title":"Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study","volume":"53","author":"Bagatin","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.isci.2025.114042_bib188","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17425255.2018.1515198","article-title":"Pharmacokinetics of tazarotene and acitretin in psoriasis","volume":"14","author":"Heath","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.isci.2025.114042_bib189","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.114042_bib190","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.antiviral.2019.04.009","article-title":"The retinoic acid receptor (RAR) \u03b1-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA","volume":"168","author":"Nkongolo","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.isci.2025.114042_bib191","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1111\/bph.15902","article-title":"A non-retinol retinoic acid receptor-\u03b3 (RAR-\u03b3\/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A-induced skin damage","volume":"179","author":"Dai","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib192","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of Fenofibrate on Progression of Diabetic Retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid."},{"key":"10.1016\/j.isci.2025.114042_bib193","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","article-title":"Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial","volume":"84","author":"Sun","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib194","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.isci.2025.114042_bib195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","article-title":"Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor\/Firsocostat","volume":"21","author":"Lawitz","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030706","article-title":"Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-\u03b1 Modulator (SPPARM\u03b1), in Dyslipidemic Patients with Renal Impairment","volume":"20","author":"Yokote","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib197","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of Pemafibrate, a Novel Selective PPAR\u03b1 Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.isci.2025.114042_bib198","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib199","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00125-024-06327-w","article-title":"Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial","volume":"68","author":"Nadeau","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2025.114042_bib200","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4093\/dmj.2023.0259","article-title":"Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial","volume":"48","author":"Park","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.isci.2025.114042_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176113","article-title":"GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPAR\u03b3\/CD36 pathway and altering the gut microbiota","volume":"960","author":"Xiao","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155233","article-title":"GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease","volume":"133","author":"Baumann","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114042_bib203","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc13-2480","article-title":"Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?","volume":"37","author":"DePaoli","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.isci.2025.114042_bib204","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2025.114042_bib205","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib206","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib207","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib209","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature11030","article-title":"Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists","volume":"485","author":"Solt","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114042_bib210","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/cb1002762","article-title":"Identification of SR3335 (ML-176): a synthetic ROR\u03b1 selective inverse agonist","volume":"6","author":"Kumar","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib211","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1074\/jbc.M210208200","article-title":"Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis","volume":"278","author":"Cao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/ATVBAHA.113.302781","article-title":"Activation of liver X receptor decreases atherosclerosis in Ldlr(-)\/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells","volume":"34","author":"Kappus","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib213","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jnr.22743","article-title":"Liver X receptors regulate cholesterol homeostasis in oligodendrocytes","volume":"90","author":"Nelissen","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.isci.2025.114042_bib214","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00165.2005","article-title":"Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob\/ob mice","volume":"289","author":"Grefhorst","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202000043","article-title":"Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques","volume":"9","author":"Benne","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.isci.2025.114042_bib216","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/CIRCHEARTFAILURE.114.001260","article-title":"Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia\/reperfusion injury","volume":"7","author":"He","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.isci.2025.114042_bib217","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137230","article-title":"Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes","volume":"5","author":"Vieira","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2025.114042_bib218","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1194\/jlr.M800376-JLR200","article-title":"Synthetic LXR agonist attenuates plaque formation in apoE-\/- mice without inducing liver steatosis and hypertriglyceridemia","volume":"50","author":"Kratzer","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib219","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cb300541g","article-title":"A liver-selective LXR inverse agonist that suppresses hepatic steatosis","volume":"8","author":"Griffett","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib220","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib221","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8071093","article-title":"Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis","volume":"2018","author":"Huang","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.isci.2025.114042_bib222","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib223","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib224","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib225","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.isci.2025.114042_bib226","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000744","article-title":"Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study","volume":"15","author":"Levy","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib227","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib228","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/2211-5463.13925","article-title":"FXR activation reduces the formation of macrophage foam cells and atherosclerotic plaque, possibly by down regulating hepatic lipase in macrophages","volume":"15","author":"Gu","year":"2025","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.isci.2025.114042_bib229","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91438.3","article-title":"Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice","volume":"13","author":"Chen","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.isci.2025.114042_bib230","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib231","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.isci.2025.114042_bib232","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.isci.2025.114042_bib233","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib234","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030443","article-title":"Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis","volume":"7","author":"Renga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib236","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","article-title":"A pooled analysis of vitamin D dose requirements for fracture prevention","volume":"367","author":"Bischoff-Ferrari","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib237","first-page":"906","article-title":"Vitamin D receptor ligands for osteoporosis","volume":"7","author":"Cheskis","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.isci.2025.114042_bib238","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1210\/clinem\/dgab114","article-title":"Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial","volume":"106","author":"Saha","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib239","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2019.09.009","article-title":"Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature","volume":"41","author":"Schuster","year":"2019","journal-title":"Clin. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7861\/clinmedicine.15-4-351","article-title":"Drug treatment of pruritus in liver diseases","volume":"15","author":"Hegade","year":"2015","journal-title":"Clin. Med."},{"key":"10.1016\/j.isci.2025.114042_bib241","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-022-04521-5","article-title":"Long-term oral administration of an HNF4\u03b1 agonist prevents weight gain and hepatic steatosis by promoting increased mitochondrial mass and function","volume":"13","author":"Veeriah","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2025.114042_bib242","article-title":"Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift","volume":"15","author":"Motlani","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.isci.2025.114042_bib243","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jgh.13976","article-title":"Estrogen receptor \u03b2 selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib244","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023745","article-title":"Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease","volume":"6","author":"Nijmeijer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib245","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1574887112666170328124539","article-title":"Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis","volume":"12","author":"Ursini","year":"2017","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.isci.2025.114042_bib246","first-page":"1777","article-title":"Effect of prednisolone and saireito co-administration on T-cells of rheumatoid arthritis patients","volume":"41","author":"Yamazaki","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.isci.2025.114042_bib247","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0961203320930099","article-title":"Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Ruiz-Irastorza","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.isci.2025.114042_bib248","article-title":"Early-Onset Multiple Sclerosis With Frequent Relapses: A Challenging Diagnosis With a Less Favorable Prognosis","volume":"13","author":"Thadchanamoorthy","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.isci.2025.114042_bib249","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.3748\/wjg.14.5471","article-title":"Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone","volume":"14","author":"Aseni","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib250","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001244","article-title":"Clinical features of Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE","volume":"11","author":"Wang","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.isci.2025.114042_bib251","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/rheumatology\/kead334","article-title":"Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis","volume":"63","author":"Kerstens","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.isci.2025.114042_bib252","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib254","first-page":"3925","article-title":"Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice","volume":"159","author":"Koorneef","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib255","doi-asserted-by":"crossref","first-page":"E337","DOI":"10.1152\/ajpendo.00018.2019","article-title":"Effects of combined glucocorticoid\/mineralocorticoid receptor modulation (CORT118335) on energy balance, adiposity, and lipid metabolism in male rats","volume":"317","author":"Nguyen","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib256","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib257","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib258","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib259","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib260","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib261","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.isci.2025.114042_bib262","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.isci.2025.114042_bib263","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2025.114042_bib264","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib265","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10741-025-10520-3","article-title":"The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment","volume":"30","author":"Taub","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib266","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib267","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.isci.2025.114042_bib268","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FJC.0b013e3182495543","article-title":"SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats","volume":"59","author":"Nariai","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib269","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000335559","article-title":"Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone\/salt-treated rats","volume":"89","author":"Nariai","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.isci.2025.114042_bib270","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","article-title":"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy","volume":"53","author":"Meyers","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib271","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.isci.2025.114042_bib272","doi-asserted-by":"crossref","first-page":"G280","DOI":"10.1152\/ajpgi.00338.2019","article-title":"Nr4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts","volume":"321","author":"Pulakazhi Venu","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108521","article-title":"Cytosporone B (Csn-B), an NR4A1 agonist, attenuates acute cardiac allograft rejection by inducing differential apoptosis of CD4+T cells","volume":"104","author":"Ding","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib274","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.4103\/1673-5374.339492","article-title":"NR4A1 agonist cytosporone B attenuates neuroinflammation in a mouse model of multiple sclerosis","volume":"17","author":"Yu","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.isci.2025.114042_bib275","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib276","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1136\/gutjnl-2020-321774","article-title":"Hepatic Kr\u00fcppel-like factor 16 (KLF16) targets PPAR\u03b1 to improve steatohepatitis and insulin resistance","volume":"70","author":"Sun","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.isci.2025.114042_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.108957","article-title":"Green tea extract increases adiponectin and PPAR \u03b1 levels to improve hepatic steatosis","volume":"103","author":"Marinovic","year":"2022","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.isci.2025.114042_bib278","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7019597","article-title":"Regulation and Mechanism of miR-518d through the PPAR\u03b1-Mediated NF-\u03baB Pathway in the Development of Gestational Diabetes Mellitus","volume":"2020","author":"Qiu","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.isci.2025.114042_bib279","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/JOE-16-0649","article-title":"Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism","volume":"234","author":"Lv","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib281","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122093","article-title":"Regulation of Ketone Body Metabolism and the Role of PPAR\u03b1","volume":"17","author":"Grabacka","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib282","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.tem.2016.02.008","article-title":"Unraveling the Effects of PPAR\u03b2\/\u03b4 on Insulin Resistance and Cardiovascular Disease","volume":"27","author":"V\u00e1zquez-Carrera","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib283","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cmet.2008.04.002","article-title":"Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity","volume":"7","author":"Kang","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib284","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1210\/en.2009-1211","article-title":"Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells","volume":"151","author":"Coll","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib285","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1172\/JCI42127","article-title":"PPAR\u03b2\/\u03b4 affects pancreatic \u03b2 cell mass and insulin secretion in mice","volume":"122","author":"Iglesias","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib286","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/diabetes.54.4.1157","article-title":"Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta","volume":"54","author":"Kr\u00e4mer","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib287","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cmet.2017.04.006","article-title":"PPAR\u03b4 Promotes Running Endurance by Preserving Glucose","volume":"25","author":"Fan","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib288","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114042_bib289","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ptr.7346","article-title":"Riligustilide alleviates hepatic insulin resistance and gluconeogenesis in T2DM mice through multitarget actions","volume":"36","author":"Qu","year":"2022","journal-title":"Phytother Res."},{"key":"10.1016\/j.isci.2025.114042_bib290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2018.02.029","article-title":"A novel PPAR\u03b1\/\u03b3 agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro","volume":"826","author":"Ren","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib291","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M049130","article-title":"Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity","volume":"56","author":"Bindesb\u00f8ll","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib292","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.2337\/diabetes.53.suppl_3.S75","article-title":"Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells","volume":"53","author":"Efanov","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib293","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1073\/pnas.0830671100","article-title":"Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue","volume":"100","author":"Laffitte","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib294","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/nm1471","article-title":"NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism","volume":"12","author":"Pei","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib295","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1210\/me.2007-0169","article-title":"Nur77 coordinately regulates expression of genes linked to glucose metabolism in skeletal muscle","volume":"21","author":"Chao","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib296","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.2337\/db09-0763","article-title":"Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77","volume":"58","author":"Chao","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib297","doi-asserted-by":"crossref","first-page":"C1111","DOI":"10.1152\/ajpcell.00315.2024","article-title":"Loss of glucose-stimulated \u03b2-cell Nr4a1 expression impairs insulin secretion and glucose homeostasis","volume":"327","author":"Herring","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib298","doi-asserted-by":"crossref","first-page":"11299","DOI":"10.1073\/pnas.1902490116","article-title":"NURR1 activation in skeletal muscle controls systemic energy homeostasis","volume":"116","author":"Amoasii","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib299","doi-asserted-by":"crossref","first-page":"E186","DOI":"10.1152\/ajpendo.00022.2016","article-title":"\u03b2-Cell deletion of Nr4a1 and Nr4a3 nuclear receptors impedes mitochondrial respiration and insulin secretion","volume":"311","author":"Reynolds","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib300","doi-asserted-by":"crossref","first-page":"E1081","DOI":"10.1152\/ajpendo.00169.2013","article-title":"6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3","volume":"305","author":"Liu","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib301","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011173","article-title":"Glucocorticoid Receptor Signaling in Diabetes","volume":"22","author":"Kokkinopoulou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib302","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091248","article-title":"Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats","volume":"9","author":"Beaudry","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib303","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2337\/diabetes.54.6.1846","article-title":"Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism","volume":"54","author":"Watts","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib304","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.metabol.2005.01.030","article-title":"Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice","volume":"54","author":"Liang","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114042_bib305","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/jpet.104.081257","article-title":"Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes","volume":"314","author":"Jacobson","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib306","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1080\/15548627.2023.2200625","article-title":"NR3C1\/Glucocorticoid receptor activation promotes pancreatic \u03b2-cell autophagy overload in response to glucolipotoxicity","volume":"19","author":"Wu","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.isci.2025.114042_bib307","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3945\/an.113.003798","article-title":"PPAR-\u03b1 as a key nutritional and environmental sensor for metabolic adaptation","volume":"4","author":"Contreras","year":"2013","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.isci.2025.114042_bib308","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib309","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.32592","article-title":"Gut-specific inhibition of PPAR\u03b1 as a novel approach of NAFLD treatment","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib310","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.celrep.2018.07.063","article-title":"Peroxisome Proliferator-Activated Receptor \u03b32 Controls the Rate of Adipose Tissue Lipid Storage and Determines Metabolic Flexibility","volume":"24","author":"Virtue","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.114042_bib311","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib312","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPAR\u03b2\/\u03b4 and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib313","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2012.12.024","article-title":"Knock-down of the oxysterol receptor LXR\u03b1 impairs cholesterol efflux in human primary macrophages: lack of compensation by LXR\u03b2 activation","volume":"86","author":"Ishibashi","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib314","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1194\/jlr.M022061","article-title":"LXR\u03b1 is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice","volume":"53","author":"Hong","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib315","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1002\/jcp.30204","article-title":"The roles of liver X receptor \u03b1 in inflammation and inflammation-associated diseases","volume":"236","author":"Zhao","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib316","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142275","article-title":"Mechanism of liver x receptor alpha in intestine, liver and adipose tissues in metabolic associated fatty liver disease","volume":"307","author":"Lei","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.isci.2025.114042_bib317","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1101\/sqb.2011.76.010702","article-title":"Transcriptional and posttranscriptional control of cholesterol homeostasis by liver X receptors","volume":"76","author":"Tontonoz","year":"2011","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib318","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI59817","article-title":"Liver LXR\u03b1 expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice","volume":"122","author":"Zhang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib319","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol Accumulation in CD11c(+) Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2025.114042_bib320","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1101\/gad.1773109","article-title":"Cooperative NCoR\/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways","volume":"23","author":"Ghisletti","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.isci.2025.114042_bib321","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.molcel.2009.07.021","article-title":"Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes","volume":"35","author":"Lee","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib322","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/1873-3468.12702","article-title":"Liver X receptors link lipid metabolism and inflammation","volume":"591","author":"Schulman","year":"2017","journal-title":"FEBS Lett."},{"key":"10.1016\/j.isci.2025.114042_bib323","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08009","article-title":"LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling","volume":"4","author":"Ito","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.isci.2025.114042_bib324","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2005.03.001","article-title":"LXRs regulate the balance between fat storage and oxidation","volume":"1","author":"Kalaany","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib325","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib326","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbrc.2011.05.059","article-title":"Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease","volume":"409","author":"Chen","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib327","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib328","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1152\/physiol.00020.2008","article-title":"The role of FXR in disorders of bile acid homeostasis","volume":"23","author":"Eloranta","year":"2008","journal-title":"Physiology"},{"key":"10.1016\/j.isci.2025.114042_bib329","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mam.2013.10.001","article-title":"Chronic cholestatic liver diseases: clues from histopathology for pathogenesis","volume":"37","author":"Pollheimer","year":"2014","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.isci.2025.114042_bib330","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib331","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41424-018-0034-3","article-title":"Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease","volume":"9","author":"Lin","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib332","doi-asserted-by":"crossref","first-page":"13493","DOI":"10.3748\/wjg.v20.i37.13493","article-title":"Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib333","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib334","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib335","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes","volume":"582","author":"Langhi","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.isci.2025.114042_bib336","article-title":"Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib337","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","article-title":"Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance","volume":"30","author":"Ma","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.isci.2025.114042_bib338","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/hep.24107","article-title":"Overexpression of cholesterol 7\u03b1-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis","volume":"53","author":"Li","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib339","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.vh.2017.04.002","article-title":"Nuclear Import and Export of the Thyroid Hormone Receptor","volume":"106","author":"Zhang","year":"2018","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.isci.2025.114042_bib340","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.isci.2025.114042_bib341","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/me.2008-0311","article-title":"Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms","volume":"23","author":"Araki","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib342","first-page":"1739","article-title":"Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol","volume":"14","author":"Gullberg","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib343","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mad.2004.06.010","article-title":"Mechanisms of glucocorticoid receptor signaling during inflammation","volume":"125","author":"Smoak","year":"2004","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.isci.2025.114042_bib344","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00281-020-00827-8","article-title":"Control of immunity by glucocorticoids in health and disease","volume":"42","author":"Shimba","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.isci.2025.114042_bib345","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095025","article-title":"PPARs as Key Mediators in the Regulation of Metabolism and Inflammation","volume":"23","author":"V\u00e1zquez-Carrera","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib346","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114042_bib347","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib348","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPAR\u03b3 in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts","volume":"25","author":"Mor\u00e1n-Salvador","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.isci.2025.114042_bib349","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.4049\/jimmunol.177.8.5248","article-title":"Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma","volume":"177","author":"Lee","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib350","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4049\/jimmunol.1800649","article-title":"Airway Epithelial Cell Peroxisome Proliferator-Activated Receptor \u03b3 Regulates Inflammation and Mucin Expression in Allergic Airway Disease","volume":"201","author":"Lakshmi","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib351","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pupt.2008.11.011","article-title":"Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs","volume":"22","author":"Sharma","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib352","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000085034","article-title":"The synthetic PPARgamma agonist troglitazone inhibits IL-5-induced CD69 upregulation and eosinophil-derived neurotoxin release from eosinophils","volume":"74","author":"Matsuwaki","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/j.isci.2025.114042_bib353","doi-asserted-by":"crossref","first-page":"G283","DOI":"10.1152\/ajpgi.00205.2016","article-title":"Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells","volume":"312","author":"Brocker","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib354","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trsl.2016.10.004","article-title":"Effect of PPAR-\u03b2\/\u03b4 agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury","volume":"182","author":"Chehaibi","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.isci.2025.114042_bib355","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635923","article-title":"Crosstalk Between LXR and Caveolin-1 Signaling Supports Cholesterol Efflux and Anti-Inflammatory Pathways in Macrophages","volume":"12","author":"Ram\u00edrez","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib356","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3389\/fimmu.2017.01929","article-title":"Platycodin D Inhibits Inflammatory Response in LPS-Stimulated Primary Rat Microglia Cells through Activating LXR\u03b1-ABCA1 Signaling Pathway","volume":"8","author":"Fu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib357","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2016.12.003","article-title":"Liver X receptors agonists suppress NLRP3 inflammasome activation","volume":"91","author":"Yu","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.isci.2025.114042_bib358","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2017.07.053","article-title":"Amelioration of amyloid \u03b2-induced retinal inflammatory responses by a LXR agonist TO901317 is associated with inhibition of the NF-\u03baB signaling and NLRP3 inflammasome","volume":"360","author":"Lei","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.isci.2025.114042_bib359","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm820","article-title":"Reciprocal regulation of inflammation and lipid metabolism by liver X receptors","volume":"9","author":"Joseph","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCRESAHA.106.135814","article-title":"Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages","volume":"101","author":"Fontaine","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib361","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcp.22022","article-title":"The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation","volume":"223","author":"Sorrentino","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib362","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2006.11.022","article-title":"Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma","volume":"25","author":"Ghisletti","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib363","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/10641963.2017.1288740","article-title":"LXR\u03b1 is expressed at higher levels in healthy people compared to atherosclerosis patients and its over-expression polarizes macrophages towards an anti-inflammatory M\u03a62 phenotype","volume":"40","author":"Liu","year":"2018","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.isci.2025.114042_bib364","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111650","article-title":"Immunomodulatory functions of FXR","volume":"551","author":"Fiorucci","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib365","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib366","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib367","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The Bile Acid Receptor GPBAR1 Regulates the M1\/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib368","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile Acids Activated Receptors Regulate Innate Immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib369","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib370","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib371","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cells10061281","article-title":"Bile Acids Activated Receptors in Inflammatory Bowel Disease","volume":"10","author":"Biagioli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib372","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1535-7163.MCT-16-0153","article-title":"A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2","volume":"15","author":"Yang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114042_bib373","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1042\/BST0390688","article-title":"Inflammation: a role for NR4A orphan nuclear receptors?","volume":"39","author":"McMorrow","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.isci.2025.114042_bib374","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/1529-0131(200104)44:4<782::AID-ANR134>3.0.CO;2-H","article-title":"Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis","volume":"44","author":"Murphy","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2025.114042_bib375","doi-asserted-by":"crossref","first-page":"29256","DOI":"10.1074\/jbc.M502606200","article-title":"Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli","volume":"280","author":"Pei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib376","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.molimm.2009.07.019","article-title":"Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis","volume":"46","author":"Aherne","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib377","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1210\/me.2005-0331","article-title":"Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77","volume":"20","author":"Pei","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib378","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1073\/pnas.0803454105","article-title":"Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines","volume":"105","author":"Doi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib379","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","article-title":"The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus","volume":"109","author":"Finck","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib380","doi-asserted-by":"crossref","first-page":"H524","DOI":"10.1152\/ajpheart.00217.2016","article-title":"Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease","volume":"313","author":"Boese","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib381","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol","volume":"374","author":"Hodis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib382","series-title":"Endotext","article-title":"Amiodarone Induced Thyrotoxicosis","author":"Macchia","year":"2000"},{"key":"10.1016\/j.isci.2025.114042_bib383","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.15387","article-title":"Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis","volume":"178","author":"Ma","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib384","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1172\/JCI38911","article-title":"LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression","volume":"120","author":"Feig","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib385","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","article-title":"A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis","volume":"7","author":"Chawla","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib386","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1194\/jlr.M300182-JLR200","article-title":"FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits","volume":"44","author":"Xu","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib387","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature03988","article-title":"A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma","volume":"437","author":"Pascual","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114042_bib388","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.15252\/embj.201489819","article-title":"An LXR-NCOA5 gene regulatory complex directs inflammatory crosstalk-dependent repression of macrophage cholesterol efflux","volume":"34","author":"Gillespie","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2025.114042_bib389","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1016\/j.celrep.2018.11.100","article-title":"LXR Suppresses Inflammatory Gene Expression and Neutrophil Migration through cis-Repression and Cholesterol Efflux","volume":"25","author":"Thomas","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.114042_bib390","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ki.2009.330","article-title":"Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury","volume":"76","author":"Li","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2025.114042_bib391","doi-asserted-by":"crossref","first-page":"F328","DOI":"10.1152\/ajprenal.00484.2007","article-title":"PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells","volume":"296","author":"Kono","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib392","first-page":"F777","article-title":"Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney","volume":"275","author":"Ouali","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib393","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/hr.2009.107","article-title":"Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats","volume":"32","author":"Shin","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.isci.2025.114042_bib394","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2337\/diabetes.55.04.06.db05-1329","article-title":"Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib395","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/ndt\/gfl212","article-title":"PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse","volume":"21","author":"Calkin","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2025.114042_bib396","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.107.129197","article-title":"Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release","volume":"324","author":"Chen","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib397","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11010-008-9917-z","article-title":"Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat","volume":"320","author":"Balakumar","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.isci.2025.114042_bib398","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1139\/Y08-043","article-title":"Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol","volume":"86","author":"Wang","year":"2008","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib399","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-\u03b1 down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib400","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ajpath.2014.06.021","article-title":"Peroxisome proliferator-activated receptor \u03b1 protects capillary pericytes in the retina","volume":"184","author":"Ding","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.isci.2025.114042_bib401","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/db11-0413","article-title":"Therapeutic effects of PPAR\u03b1 agonists on diabetic retinopathy in type 1 diabetes models","volume":"62","author":"Chen","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib402","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208399","article-title":"Neuroprotective effects of PPAR\u03b1 in retinopathy of type 1 diabetes","volume":"14","author":"Pearsall","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib403","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib404","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MNH.0b013e32834de526","article-title":"PPAR\u03b3 as a therapeutic target in diabetic nephropathy and other renal diseases","volume":"21","author":"Yang","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.isci.2025.114042_bib405","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/818530","article-title":"New Insights into the PPAR \u03b3 Agonists for the Treatment of Diabetic Nephropathy","volume":"2014","author":"Jia","year":"2014","journal-title":"PPAR Res."},{"key":"10.1016\/j.isci.2025.114042_bib406","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/jpbs.jpbs_497_21","article-title":"Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?","volume":"13","author":"Aziz","year":"2021","journal-title":"J. Pharm. BioAllied Sci."},{"key":"10.1016\/j.isci.2025.114042_bib407","article-title":"The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib408","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1152\/ajprenal.00152.2007","article-title":"PPARs and the kidney in metabolic syndrome","volume":"294","author":"Ruan","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib409","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2009.01.010","article-title":"Emerging role of PPAR ligands in the management of diabetic nephropathy","volume":"60","author":"Balakumar","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2025.114042_bib410","doi-asserted-by":"crossref","first-page":"F886","DOI":"10.1152\/ajprenal.00123.2004","article-title":"Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells","volume":"287","author":"Wu","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib411","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/db06-1134","article-title":"Peroxisome proliferator activated receptor alpha\/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db\/db mice","volume":"56","author":"Cha","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib412","first-page":"410","article-title":"The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk","volume":"10","author":"T\u00f6njes","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.isci.2025.114042_bib413","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2337\/dc11-2142","article-title":"Peroxisome proliferator-activated receptor \u03b3 polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.isci.2025.114042_bib414","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.isci.2025.114042_bib415","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(07)61608-0","article-title":"Fenofibrate for diabetic retinopathy","volume":"370","author":"Sim\u00f3","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib416","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a Dual PPAR \u03b1\/\u03b3 agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial","volume":"9","author":"Jain","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib417","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174032","article-title":"Effect of dual PPAR-\u03b1\/\u03b3 agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy","volume":"899","author":"Joharapurkar","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib418","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.2337\/db05-0603","article-title":"Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes","volume":"55","author":"Proctor","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib419","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1152\/ajprenal.00396.2007","article-title":"LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes","volume":"294","author":"Kelly","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib420","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/labinvest.2010.7","article-title":"Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system","volume":"90","author":"Kuipers","year":"2010","journal-title":"Lab. Invest."},{"key":"10.1016\/j.isci.2025.114042_bib421","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/0115733998259273231101052549","article-title":"Lipids: A Major Culprit in Diabetic Nephropathy","volume":"20","author":"Beniwal","year":"2024","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.isci.2025.114042_bib422","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1073\/pnas.1200588109","article-title":"Central diabetes insipidus associated with impaired renal aquaporin-1 expression in mice lacking liver X receptor \u03b2","volume":"109","author":"Gabbi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib423","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0975-3583.83035","article-title":"Inflammation and diabetic retinal microvascular complications","volume":"2","author":"Zhang","year":"2011","journal-title":"J. Cardiovasc. Dis. Res."},{"key":"10.1016\/j.isci.2025.114042_bib424","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archopht.126.9.1266","article-title":"Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients","volume":"126","author":"Kowluru","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.isci.2025.114042_bib425","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.2337\/db11-1596","article-title":"Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes","volume":"61","author":"Hazra","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib426","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1194\/jlr.M021188","article-title":"Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation","volume":"53","author":"Cermenati","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib427","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14604-0","article-title":"LXR agonist modifies neuronal lipid homeostasis and decreases PGD2 in the dorsal root ganglia in western diet-fed mice","volume":"12","author":"Elshareif","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib428","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121595","article-title":"NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus","volume":"8","author":"Ferreira","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib429","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/db16-1354","article-title":"Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ER\u03b1\/HGF\/Met Pathway","volume":"66","author":"Zhang","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib430","doi-asserted-by":"crossref","first-page":"F519","DOI":"10.1152\/ajprenal.00135.2024","article-title":"The mineralocorticoid receptor in diabetic kidney disease","volume":"327","author":"Jia","year":"2024","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib431","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2025.114042_bib432","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib433","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107747","article-title":"Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents","volume":"187","author":"Canonica","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.isci.2025.114042_bib434","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib435","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1167\/iovs.17-23073","article-title":"Aldosterone Exposure Causes Increased Retinal Edema and Severe Retinopathy Following Laser-Induced Retinal Vein Occlusion in Mice","volume":"59","author":"Allingham","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib436","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.2337\/db21-0099","article-title":"Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy","volume":"70","author":"Zhao","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib437","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrneph.2010.56","article-title":"Nuclear hormone receptors in diabetic nephropathy","volume":"6","author":"Wang","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2025.114042_bib438","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.ki.5002572","article-title":"Renoprotective role of the vitamin D receptor in diabetic nephropathy","volume":"73","author":"Zhang","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2025.114042_bib439","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3803\/EnM.2015.30.4.469","article-title":"Association between Bsm1 Polymorphism in Vitamin D Receptor Gene and Diabetic Retinopathy of Type 2 Diabetes in Korean Population","volume":"30","author":"Hong","year":"2015","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263346","article-title":"Metabolic impact of the VDR rs1544410 in diabetic retinopathy","volume":"17","author":"Assis","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib441","doi-asserted-by":"crossref","first-page":"891","DOI":"10.4314\/ahs.v18i4.7","article-title":"Association of FokI, TaqI, BsmI and ApaI polymorphisms with diabetic retinopathy: a pooled analysis of case-control studies","volume":"18","author":"Jiao","year":"2018","journal-title":"Afr. Health Sci."},{"key":"10.1016\/j.isci.2025.114042_bib442","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2042018817708910","article-title":"Expression of JAZF1, ABCC8, KCNJ11and Notch2 genes and vitamin D receptor polymorphisms in type 2 diabetes, and their association with microvascular complications","volume":"8","author":"Rasheed","year":"2017","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib443","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/jme.0.0270011","article-title":"Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences","volume":"27","author":"Ryffel","year":"2001","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib444","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/db07-1065","article-title":"HNF4 alpha and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy","volume":"57","author":"Niehof","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib445","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib446","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1152\/ajprenal.00404.2009","article-title":"The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib447","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019437","article-title":"Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus","volume":"10","author":"Srivastava","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.isci.2025.114042_bib448","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/s41467-021-22617-y","article-title":"Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy","volume":"12","author":"Srivastava","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib449","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085594","article-title":"Nuclear hormone receptor expression in mouse kidney and renal cell lines","volume":"9","author":"Ogawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib450","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.genm.2008.03.010","article-title":"Estrogens and the diabetic kidney","volume":"5","author":"Maric","year":"2008","journal-title":"Gend. Med."},{"key":"10.1016\/j.isci.2025.114042_bib451","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ki.2009.69","article-title":"17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes","volume":"75","author":"Catanuto","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2025.114042_bib452","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib453","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib454","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.isci.2025.114042_bib455","first-page":"36","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib456","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib457","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib458","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.15314","article-title":"Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications","volume":"50","author":"Jayakumar","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib459","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hep.32538","article-title":"Intestinal peroxisome proliferator-activated receptor \u03b1-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis","volume":"77","author":"Yan","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib460","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154342","article-title":"Revealing the role of peroxisome proliferator-activated receptor \u03b2\/\u03b4 in nonalcoholic fatty liver disease","volume":"114","author":"Zarei","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.isci.2025.114042_bib461","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MOL.0b013e3282f9b54d","article-title":"Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism","volume":"19","author":"Flowers","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.isci.2025.114042_bib462","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPAR\u03b2\/\u03b4: A Key Therapeutic Target in Metabolic Disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib463","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib464","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib465","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.1203218109","article-title":"Nuclear receptor PPAR\u03b3-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib466","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1074\/jbc.M210062200","article-title":"Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression","volume":"278","author":"Yu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib467","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-022-04629-z","article-title":"Hepatocyte PPAR\u03b3 contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice","volume":"80","author":"Lee","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2025.114042_bib468","doi-asserted-by":"crossref","DOI":"10.3390\/genes12050645","article-title":"The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD","volume":"12","author":"Dixon","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.isci.2025.114042_bib469","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-023-03586-1","article-title":"The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review","volume":"80","author":"Zachou","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2025.114042_bib471","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib472","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib473","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1751-2980.2011.00554.x","article-title":"Liver X receptors bridge hepatic lipid metabolism and inflammation","volume":"13","author":"Liu","year":"2012","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.isci.2025.114042_bib474","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","article-title":"Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease","volume":"59","author":"Ahn","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib475","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biopha.2017.10.035","article-title":"Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism","volume":"97","author":"Zhou","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2025.114042_bib476","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/bph.13933","article-title":"Morin, a novel liver X receptor \u03b1\/\u03b2 dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases","volume":"174","author":"Gu","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib477","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1021\/acs.jnatprod.6b00146","article-title":"The Flavone Luteolin Inhibits Liver X Receptor Activation","volume":"79","author":"Francisco","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.isci.2025.114042_bib478","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1080\/13880209.2016.1187179","article-title":"Curcumin inhibits hyperlipidemia and hepatic fat accumulation in high-fructose-fed male Wistar rats","volume":"54","author":"Maithilikarpagaselvi","year":"2016","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib479","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.isci.2025.114042_bib480","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2025.114042_bib481","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib482","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","article-title":"Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs","volume":"15","author":"Ahmad","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib483","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib484","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312797","article-title":"Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD","volume":"22","author":"Mavromati","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328333a1dd","article-title":"The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease","volume":"20","author":"Sookoian","year":"2010","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.isci.2025.114042_bib486","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2025.114042_bib487","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00204-014-1348-x","article-title":"Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms","volume":"89","author":"Bitter","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.isci.2025.114042_bib488","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2337\/db12-1039","article-title":"PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice","volume":"62","author":"He","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib489","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/CM9.0000000000002092","article-title":"Hepatocyte nuclear factor 4\u03b1 in the pathogenesis of non-alcoholic fatty liver disease","volume":"135","author":"Pan","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.isci.2025.114042_bib490","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.32326","article-title":"Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans","volume":"76","author":"Gunewardena","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib491","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/hep.31604","article-title":"Hepatocyte Nuclear Factor 4\u03b1 Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice)","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib492","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/MCB.21.4.1393-1403.2001","article-title":"Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis","volume":"21","author":"Hayhurst","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.114042_bib493","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.3748\/wjg.v13.i42.5635","article-title":"Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse","volume":"13","author":"Baskin-Bey","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib494","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.12.019","article-title":"Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice","volume":"154","author":"Pourcet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2025.114042_bib495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236000","article-title":"REV-ERB agonism improves liver pathology in a mouse model of NASH","volume":"15","author":"Griffett","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib496","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041260","article-title":"The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis","volume":"19","author":"Xu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib497","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174562","article-title":"PPAR-gamma agonists: Potential modulators of autophagy in obesity","volume":"912","author":"Faghfouri","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib498","article-title":"Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7\/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib499","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3858\/emm.2009.41.6.045","article-title":"Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice","volume":"41","author":"Jeong","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.isci.2025.114042_bib500","doi-asserted-by":"crossref","first-page":"743","DOI":"10.12659\/MSM.897307","article-title":"PPAR-\u03b1 Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia","volume":"22","author":"Feng","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.isci.2025.114042_bib501","doi-asserted-by":"crossref","first-page":"43112","DOI":"10.1074\/jbc.M111.252775","article-title":"Peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) induces PPAR\u03b3 coactivator 1\u03b1 (PGC-1\u03b1) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16","volume":"286","author":"Hondares","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib502","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cbf.3111","article-title":"PPAR-\u03b1 agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice","volume":"33","author":"Rachid","year":"2015","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.isci.2025.114042_bib503","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00027.2013","article-title":"Physiological functions of peroxisome proliferator-activated receptor \u03b2","volume":"94","author":"Neels","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114042_bib505","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1097-2765(00)80209-9","article-title":"PPAR gamma is required for placental, cardiac, and adipose tissue development","volume":"4","author":"Barak","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib506","doi-asserted-by":"crossref","first-page":"18656","DOI":"10.1073\/pnas.1314863110","article-title":"Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR\u03b3","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib507","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","article-title":"PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance","volume":"4","author":"Kubota","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114042_bib508","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/MCB.24.8.3430-3444.2004","article-title":"Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression","volume":"24","author":"Seo","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.114042_bib509","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101913","article-title":"Adipose tissue peroxisomal lipid synthesis orchestrates obesity and insulin resistance through LXR-dependent lipogenesis","volume":"82","author":"Kleiboeker","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib510","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/oby.24158","article-title":"LXR regulation of adipose tissue inflammation during obesity is associated with dysregulated macrophage function","volume":"33","author":"da Silva Pereira","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.isci.2025.114042_bib511","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.729828","article-title":"Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders","volume":"12","author":"Appelman","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib512","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000450909","article-title":"Farnesoid X Receptor an Emerging Target to Combat Obesity","volume":"35","author":"De Magalhaes Filho","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.isci.2025.114042_bib513","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114042_bib514","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib515","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib516","doi-asserted-by":"crossref","DOI":"10.3390\/nu15224832","article-title":"Interplay between Vitamin D and Adipose Tissue: Implications for Adipogenesis and Adipose Tissue Function","volume":"15","author":"Lu","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2025.114042_bib517","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172761","article-title":"VDR regulates energy metabolism by modulating remodeling in adipose tissue","volume":"865","author":"Xu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib518","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1439-0396.2012.01308.x","article-title":"Differences in triglyceride and cholesterol metabolism and resistance to obesity in male and female vitamin D receptor knockout mice","volume":"97","author":"Weber","year":"2013","journal-title":"J. Anim. Physiol. Anim. Nutr."},{"key":"10.1016\/j.isci.2025.114042_bib519","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1074\/jbc.M510343200","article-title":"Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells","volume":"281","author":"Blumberg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib520","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4162\/nrp.2020.14.6.553","article-title":"Vitamin D regulation of adipogenesis and adipose tissue functions","volume":"14","author":"Nimitphong","year":"2020","journal-title":"Nutr. Res. Pract."},{"key":"10.1016\/j.isci.2025.114042_bib521","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1210\/en.2008-0718","article-title":"Mice lacking the thyroid hormone receptor-alpha gene spend more energy in thermogenesis, burn more fat, and are less sensitive to high-fat diet-induced obesity","volume":"149","author":"Pelletier","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib522","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jsbmb.2008.06.010","article-title":"Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141","volume":"111","author":"Bryzgalova","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib523","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI41702","article-title":"Genetic rescue of nonclassical ER\u03b1 signaling normalizes energy balance in obese Er\u03b1-null mutant mice","volume":"121","author":"Park","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib524","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00125-005-0105-3","article-title":"Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver","volume":"49","author":"Bryzgalova","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2025.114042_bib525","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000339563","article-title":"Loss of Estrogen Receptor \u03b1 Signaling Leads to Insulin Resistance and Obesity in Young and Adult Female Mice","volume":"2","author":"Manrique","year":"2012","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.isci.2025.114042_bib526","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-024-47687-6","article-title":"An estrogen receptor \u03b1-derived peptide improves glucose homeostasis during obesity","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib527","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.ijo.0802522","article-title":"Expression of estrogen receptors in the coronary arteries of young and premenopausal women in relation to central obesity","volume":"28","author":"Kortelainen","year":"2004","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.isci.2025.114042_bib528","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/andr.12055","article-title":"Hematopoietic androgen receptor deficiency promotes visceral fat deposition in male mice without impairing glucose homeostasis","volume":"3","author":"Rubinow","year":"2015","journal-title":"Andrology"},{"key":"10.1016\/j.isci.2025.114042_bib529","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jc.2011-3123","article-title":"Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI","volume":"97","author":"Geer","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib530","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1152\/ajpendo.00478.2015","article-title":"The glucocorticoid receptor: cause of or cure for obesity?","volume":"310","author":"John","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib531","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/labinvest.2010.170","article-title":"DNA binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kr\u00fcppel-like factor 15 gene expression","volume":"91","author":"Asada","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.isci.2025.114042_bib532","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116137","article-title":"Adipose tissue in cortisol excess: What Cushing's syndrome can teach us?","volume":"223","author":"Bavaresco","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib533","first-page":"224","article-title":"Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes","volume":"98","author":"Imai","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib534","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.M511116200","article-title":"A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway","volume":"281","author":"Zhou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib535","doi-asserted-by":"crossref","first-page":"25984","DOI":"10.1074\/jbc.M109.016808","article-title":"The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity","volume":"284","author":"Gao","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib536","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jare.2024.03.020","article-title":"PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets","volume":"69","author":"Zheng","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.isci.2025.114042_bib537","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/00005344-200212000-00003","article-title":"Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells","volume":"40","author":"Martin-Nizard","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib538","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1540\/jsmr.44.41","article-title":"Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals","volume":"44","author":"Matsumoto","year":"2008","journal-title":"J. Smooth Muscle Res."},{"key":"10.1016\/j.isci.2025.114042_bib539","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2008.05.055","article-title":"Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation","volume":"203","author":"Kitajima","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.isci.2025.114042_bib540","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijcard.2009.03.100","article-title":"Comparison of PPAR\u03b4 and PPAR\u03b3 in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells","volume":"143","author":"Liang","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib541","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2005.09.008","article-title":"Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells","volume":"187","author":"Wang","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.isci.2025.114042_bib542","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.brainres.2012.09.012","article-title":"PPAR\u03b4 agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice","volume":"1483","author":"Santhanam","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.isci.2025.114042_bib543","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","article-title":"Submaximal PPAR\u03b3 activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders","volume":"166","author":"Balakumar","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib544","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00490.2015","article-title":"Endothelial PPAR-\u03b3 provides vascular protection from IL-1\u03b2-induced oxidative stress","volume":"310","author":"Mukohda","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib545","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbadis.2014.12.019","article-title":"Treatment in vitro with PPAR\u03b1 and PPAR\u03b3 ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice","volume":"1852","author":"Penas","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2025.114042_bib546","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor","volume":"325","author":"Zelcer","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.114042_bib547","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","article-title":"LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE\u22173Leiden mice: time course and mechanisms","volume":"50","author":"Verschuren","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib548","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI27883","article-title":"Liver X receptors as integrators of metabolic and inflammatory signaling","volume":"116","author":"Zelcer","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib549","doi-asserted-by":"crossref","first-page":"34182","DOI":"10.1074\/jbc.M204887200","article-title":"Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles","volume":"277","author":"Grefhorst","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib550","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib551","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvm016","article-title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells","volume":"77","author":"Li","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib552","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1194\/jlr.M800619-JLR200","article-title":"Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-\/- and apoE-\/- mice","volume":"50","author":"Hartman","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib553","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib554","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","article-title":"Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"46","author":"Hanniman","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib555","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14728222.2017.1279146","article-title":"The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases","volume":"21","author":"Rodr\u00edguez-Calvo","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.isci.2025.114042_bib556","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2012.05.014","article-title":"Nuclear Receptors in atherosclerosis: a superfamily with many 'Goodfellas","volume":"368","author":"Kurakula","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib557","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.yjmcc.2010.03.023","article-title":"Nuclear receptor Nur77 suppresses inflammatory response dependent on COX-2 in macrophages induced by oxLDL","volume":"49","author":"Shao","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib558","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.260760","article-title":"Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis","volume":"110","author":"Hamers","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib559","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCRESAHA.111.253377","article-title":"NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis","volume":"110","author":"Hanna","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib560","article-title":"Nur77 decreases atherosclerosis progression in apoE(-\/-) mice fed a high-fat\/high-cholesterol diet","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib561","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1161\/CIRCULATIONAHA.109.885673","article-title":"Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation","volume":"121","author":"Bonta","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib562","doi-asserted-by":"crossref","first-page":"18304","DOI":"10.1074\/jbc.M115.638064","article-title":"Nuclear Receptor Nr4a2 Promotes Alternative Polarization of Macrophages and Confers Protection in Sepsis","volume":"290","author":"Mahajan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib563","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/stem.1747","article-title":"Deficiency of the NR4A orphan nuclear receptor NOR1 in hematopoietic stem cells accelerates atherosclerosis","volume":"32","author":"Qing","year":"2014","journal-title":"Stem Cell."},{"key":"10.1016\/j.isci.2025.114042_bib564","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12872-017-0701-4","article-title":"Deletion of the NR4A nuclear receptor NOR1 in hematopoietic stem cells reduces inflammation but not abdominal aortic aneurysm formation","volume":"17","author":"Qing","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.isci.2025.114042_bib565","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCRESAHA.110.222083","article-title":"Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis","volume":"107","author":"Zhao","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib566","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030313","article-title":"Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia","volume":"11","author":"Karpale","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114042_bib567","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1194\/jlr.M017376","article-title":"Deficiency of PXR decreases atherosclerosis in apoE-deficient mice","volume":"52","author":"Sui","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.isci.2025.114042_bib568","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249436","article-title":"PPARs and Myocardial Infarction","volume":"21","author":"Wagner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib569","doi-asserted-by":"crossref","first-page":"H87","DOI":"10.1152\/ajpheart.00285.2005","article-title":"Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia","volume":"290","author":"Sambandam","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib570","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lfs.2014.03.019","article-title":"Cardiomyocyte specific peroxisome proliferator-activated receptor-\u03b1 overexpression leads to irreversible damage in ischemic murine heart","volume":"102","author":"Duerr","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.isci.2025.114042_bib571","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1161\/01.CIR.0000093187.42015.6C","article-title":"Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia\/reperfusion injury","volume":"108","author":"Yue","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib572","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1096\/fj.01-0793com","article-title":"Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size","volume":"16","author":"Wayman","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.isci.2025.114042_bib573","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.RES.0000060700.55247.7C","article-title":"Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta\/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism","volume":"92","author":"Gilde","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib574","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm1116","article-title":"Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy","volume":"10","author":"Cheng","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114042_bib575","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/cr.2017.84","article-title":"Live cell screening platform identifies PPAR\u03b4 as a regulator of cardiomyocyte proliferation and cardiac repair","volume":"27","author":"Magadum","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2025.114042_bib576","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cardiores.2007.06.027","article-title":"Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage","volume":"76","author":"Ding","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib577","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.isci.2025.114042_bib578","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib579","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.114042_bib580","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000100870","article-title":"Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats","volume":"79","author":"Cao","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.isci.2025.114042_bib581","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/SHK.0b013e31815dbdc3","article-title":"Rosiglitazone is cardioprotective in a murine model of myocardial I\/R","volume":"30","author":"Mersmann","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.isci.2025.114042_bib582","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvn308","article-title":"Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists","volume":"81","author":"Liu","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib583","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176398","article-title":"Gabapentin attenuates cardiac remodeling after myocardial infarction by inhibiting M1 macrophage polarization through the peroxisome proliferator-activated receptor-\u03b3 pathway","volume":"967","author":"Li","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib584","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib585","first-page":"593","article-title":"T-Cell Mineralocorticoid Receptor Deficiency Attenuates Pathologic Ventricular Remodelling After Myocardial Infarction","volume":"39","author":"Wang","year":"2023","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib586","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib587","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib588","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.isci.2025.114042_bib589","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2017.05.072","article-title":"Deficiency of liver-X-receptor-\u03b1 reduces glucose uptake and worsens post-myocardial infarction remodeling","volume":"488","author":"Ji","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib590","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1161\/01.CIR.0000164262.08004.BB","article-title":"Female mice lacking estrogen receptor beta display prolonged ventricular repolarization and reduced ventricular automaticity after myocardial infarction","volume":"111","author":"Korte","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib591","doi-asserted-by":"crossref","first-page":"R972","DOI":"10.1152\/ajpregu.00045.2009","article-title":"Estrogen receptor beta mediates increased activation of PI3K\/Akt signaling and improved myocardial function in female hearts following acute ischemia","volume":"296","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib592","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/CS20150609","article-title":"Cardiomyocyte-specific overexpression of oestrogen receptor \u03b2 improves survival and cardiac function after myocardial infarction in female and male mice","volume":"130","author":"Schuster","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib593","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10557-020-06949-3","article-title":"Oestrogen Receptor \u03b2 Activation Protects Against Myocardial Infarction via Notch1 Signalling","volume":"34","author":"Du","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.isci.2025.114042_bib594","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-022-00754-1","article-title":"Glucocorticoid receptor inhibition promotes cardiac repair after MI","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib595","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s44161-022-00090-0","article-title":"Glucocorticoid receptor antagonization propels endogenous cardiomyocyte proliferation and cardiac regeneration","volume":"1","author":"Pianca","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib596","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101986","article-title":"Glucocorticoid Receptor Antagonism and Cardiomyocyte Regeneration Following Myocardial Infarction: A Systematic Review","volume":"48","author":"Sethi","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib597","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/biomedicines10061274","article-title":"Modulation of Rxr\u03b1 Expression in Mononuclear Phagocytes Impacts on Cardiac Remodeling after Ischemia-Reperfusion Injury","volume":"10","author":"R\u00e4uber","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.114042_bib598","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166441","article-title":"Kallistatin\/Serpina3c inhibits cardiac fibrosis after myocardial infarction by regulating glycolysis via Nr4a1 activation","volume":"1868","author":"Ji","year":"2022","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.isci.2025.114042_bib599","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/CIRCRESAHA.114.303204","article-title":"Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium","volume":"114","author":"Hilgendorf","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib600","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41420-017-0011-8","article-title":"NR4A2 protects cardiomyocytes against myocardial infarction injury by promoting autophagy","volume":"4","author":"Liu","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.isci.2025.114042_bib601","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2025.114042_bib602","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib603","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/JOE-21-0323","article-title":"Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers","volume":"253","author":"Karthigan","year":"2022","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib604","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchf.2014.07.015","article-title":"Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33\/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction","volume":"3","author":"Lax","year":"2015","journal-title":"JACC. Heart Fail."},{"key":"10.1016\/j.isci.2025.114042_bib605","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/CIRCRESAHA.119.316100","article-title":"A Critical Role for Estrogen-Related Receptor Signaling in Cardiac Maturation","volume":"126","author":"Sakamoto","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib606","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-010-9208-0","article-title":"Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure","volume":"17","author":"Sarma","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib607","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12933-024-02417-6","article-title":"Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes","volume":"23","author":"Park","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.isci.2025.114042_bib608","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FJC.0b013e31804b4163","article-title":"PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure","volume":"50","author":"Jucker","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib609","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cardiores.2007.04.026","article-title":"Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts","volume":"75","author":"Teunissen","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib610","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0303","article-title":"PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation","volume":"10","author":"Legchenko","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.114042_bib611","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejphar.2013.05.021","article-title":"PPAR-\u03b3 activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1","volume":"715","author":"Hou","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib612","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1159\/000369747","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) through NF-\u03baB\/Brg1 and TGF-\u03b21 pathways attenuates cardiac remodeling in pressure-overloaded rat hearts","volume":"35","author":"Qi","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.isci.2025.114042_bib613","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ebiom.2017.03.021","article-title":"Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-\u03b3\/AKT Pathways","volume":"18","author":"Ma","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.114042_bib614","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/HJH.0b013e32834a4d03","article-title":"Transforming growth factor-\u03b2 inhibits myocardial PPAR\u03b3 expression in pressure overload-induced cardiac fibrosis and remodeling in mice","volume":"29","author":"Gong","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.isci.2025.114042_bib615","doi-asserted-by":"crossref","DOI":"10.1038\/srep15404","article-title":"Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling","volume":"5","author":"Medzikovic","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib616","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1111\/bph.13091","article-title":"The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1","volume":"172","author":"Feng","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib617","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/CS20191014","article-title":"Neuron-derived orphan receptor-1 modulates cardiac gene expression and exacerbates angiotensin II-induced cardiac hypertrophy","volume":"134","author":"Ca\u00f1es","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib618","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0030-1255035","article-title":"Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism","volume":"42","author":"Pantos","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.isci.2025.114042_bib619","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1582-4934.2010.01014.x","article-title":"Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats","volume":"15","author":"Forini","year":"2011","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.isci.2025.114042_bib620","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrcardio.2016.174","article-title":"Thyroid hormones and cardiovascular disease","volume":"14","author":"Jabbar","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib621","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau9685","article-title":"Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice","volume":"12","author":"Oakley","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2025.114042_bib622","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22847","article-title":"Vitamin D levels and vitamin D receptor variants are associated with chronic heart failure in Chinese patients","volume":"33","author":"Hao","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.isci.2025.114042_bib623","doi-asserted-by":"crossref","DOI":"10.3390\/nu13093117","article-title":"Vitamin D Receptor Gene Polymorphism and Vitamin D Status in Population of Patients with Cardiovascular Disease-A Preliminary Study","volume":"13","author":"Abouzid","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2025.114042_bib624","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2009.10.027","article-title":"Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm","volume":"210","author":"Golledge","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.isci.2025.114042_bib625","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ajpath.2012.04.015","article-title":"Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model","volume":"181","author":"Krishna","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.isci.2025.114042_bib626","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/1389450119666171227224655","article-title":"Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm","volume":"19","author":"Rowbotham","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.isci.2025.114042_bib627","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009866","article-title":"Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial","volume":"7","author":"Pinchbeck","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.isci.2025.114042_bib628","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2014.03.138","article-title":"PPAR\u03b4 reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice by regulating extracellular matrix homeostasis and inflammatory responses","volume":"174","author":"Hwang","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib629","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/CIRCULATIONAHA.109.852467","article-title":"Rosiglitazone reduces the development and rupture of experimental aortic aneurysms","volume":"119","author":"Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib630","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11748-015-0576-1","article-title":"PPAR-\u03b3 agonist attenuates inflammation in aortic aneurysm patients","volume":"63","author":"Motoki","year":"2015","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.isci.2025.114042_bib631","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/aje\/154.3.236","article-title":"Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Troms\u00f8 Study","volume":"154","author":"Singh","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.isci.2025.114042_bib632","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1161\/01.ATV.0000143386.26399.84","article-title":"Gender differences in experimental aortic aneurysm formation","volume":"24","author":"Ailawadi","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib633","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/01.ATV.0000085842.20866.6A","article-title":"17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice","volume":"23","author":"Martin-McNulty","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib634","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jvs.2004.09.033","article-title":"Tamoxifen up-regulates catalase production, inhibits vessel wall neutrophil infiltration, and attenuates development of experimental abdominal aortic aneurysms","volume":"41","author":"Grigoryants","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.isci.2025.114042_bib635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.maturitas.2016.11.005","article-title":"Differential expression of sex hormone receptors in abdominal aortic aneurysms","volume":"96","author":"Villard","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.isci.2025.114042_bib636","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jvs.2015.11.038","article-title":"Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation","volume":"63","author":"Davis","year":"2016","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.isci.2025.114042_bib637","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/ATVBAHA.107.160382","article-title":"Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice","volume":"28","author":"Henriques","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib638","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jvs.2010.02.012","article-title":"An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance","volume":"52","author":"Thompson","year":"2010","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.isci.2025.114042_bib639","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jss.2013.05.002","article-title":"Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model","volume":"185","author":"Kurobe","year":"2013","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.isci.2025.114042_bib640","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/ATVBAHA.112.300820","article-title":"Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt","volume":"33","author":"Liu","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib641","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bjp.0706098","article-title":"Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms","volume":"144","author":"Cassis","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib642","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1161\/ATVBAHA.116.307530","article-title":"Vitamin D Receptor Activation Reduces Angiotensin-II-Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E-Knockout Mice","volume":"36","author":"Martorell","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib643","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021707","article-title":"Nuclear Receptor Nur77 Protects Against Abdominal Aortic Aneurysm by Ameliorating Inflammation Via Suppressing LOX-1","volume":"10","author":"Zhang","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.isci.2025.114042_bib644","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/HYPERTENSIONAHA.120.16078","article-title":"High NOR-1 (Neuron-Derived Orphan Receptor 1) Expression Strengthens the Vascular Wall Response to Angiotensin II Leading to Aneurysm Formation in Mice","volume":"77","author":"Ca\u00f1es","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.isci.2025.114042_bib645","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.123.065202","article-title":"LXR\u03b1 Promotes Abdominal Aortic Aneurysm Formation Through UHRF1 Epigenetic Modification of miR-26b-3p","volume":"150","author":"Guo","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib646","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103397","article-title":"Activation of nuclear receptor pregnane-X-receptor protects against abdominal aortic aneurysm by inhibiting oxidative stress","volume":"77","author":"Shen","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.isci.2025.114042_bib647","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126491","article-title":"Roles of Nuclear Receptors in Vascular Calcification","volume":"22","author":"Chinetti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib648","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1681\/ASN.2007080902","article-title":"Vitamin D receptor activators can protect against vascular calcification","volume":"19","author":"Mathew","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2025.114042_bib649","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083584","article-title":"Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification","volume":"8","author":"Han","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib650","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/ATVBAHA.113.302525","article-title":"Role of local versus systemic vitamin D receptors in vascular calcification","volume":"34","author":"Lomashvili","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib651","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035316","article-title":"Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice","volume":"7","author":"Schmidt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib652","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/ncomms2087","article-title":"The nuclear hormone receptor PPAR\u03b3 counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells","volume":"3","author":"Woldt","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib653","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00395-012-0306-0","article-title":"Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products","volume":"107","author":"Li","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.isci.2025.114042_bib654","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/ATVBAHA.112.300794","article-title":"Pioglitazone attenuates valvular calcification induced by hypercholesterolemia","volume":"33","author":"Chu","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib655","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3892\/mmr.2017.7308","article-title":"Effect of pioglitazone on the calcification of rat vascular smooth muscle cells through the downregulation of the Wnt\/\u03b2-catenin signaling pathway","volume":"16","author":"Gao","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib656","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3892\/etm.2016.3996","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 inhibits vascular calcification by upregulating Klotho","volume":"13","author":"Cheng","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.isci.2025.114042_bib657","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12013-012-9490-7","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands retard cultured vascular smooth muscle cells calcification induced by high glucose","volume":"66","author":"Zhou","year":"2013","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.isci.2025.114042_bib658","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/17085381211051477","article-title":"Ligustrazine activate the PPAR-\u03b3 pathway and play a protective role in vascular calcification","volume":"30","author":"Li","year":"2022","journal-title":"Vascular"},{"key":"10.1016\/j.isci.2025.114042_bib659","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s10020-024-00997-3","article-title":"Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-\u03b3\/FDX1 signaling","volume":"30","author":"Qi","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.isci.2025.114042_bib660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115379","article-title":"Oleoylethanolamide alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPAR\u03b1","volume":"208","author":"Chen","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib661","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.febslet.2009.03.039","article-title":"T0901317, an LXR agonist, augments PKA-induced vascular cell calcification","volume":"583","author":"Hsu","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.isci.2025.114042_bib662","doi-asserted-by":"crossref","first-page":"23938","DOI":"10.1074\/jbc.M111.237065","article-title":"Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells","volume":"286","author":"Ting","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib663","first-page":"653","article-title":"An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model","volume":"19","author":"Wang","year":"2010","journal-title":"J. Heart Valve Dis."},{"key":"10.1016\/j.isci.2025.114042_bib664","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.ATV.0000258414.59393.89","article-title":"Mineralocorticoid receptor activation promotes vascular cell calcification","volume":"27","author":"Jaffe","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib665","doi-asserted-by":"crossref","first-page":"F967","DOI":"10.1152\/ajprenal.00669.2014","article-title":"Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification","volume":"309","author":"Tatsumoto","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib666","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10495-020-01592-7","article-title":"Lactate accelerates vascular calcification through NR4A1-regulated mitochondrial fission and BNIP3-related mitophagy","volume":"25","author":"Zhu","year":"2020","journal-title":"Apoptosis"},{"key":"10.1016\/j.isci.2025.114042_bib667","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/humu.20902","article-title":"Haplotypes of the NR4A2\/NURR1 gene and cardiovascular disease: the Rotterdam Study","volume":"30","author":"Kardys","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.isci.2025.114042_bib668","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCRESAHA.109.212969","article-title":"Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-\/- mice with chronic kidney disease","volume":"106","author":"Miyazaki-Anzai","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib669","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s42003-020-1058-2","article-title":"Farnesoid X receptor activation inhibits TGFBR1\/TAK1-mediated vascular inflammation and calcification via miR-135a-5p","volume":"3","author":"Li","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib670","doi-asserted-by":"crossref","first-page":"857","DOI":"10.34067\/KID.0007502020","article-title":"Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation","volume":"2","author":"Miyazaki-Anzai","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.isci.2025.114042_bib671","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/ATVBAHA.117.309054","article-title":"Estrogen Receptor Control of Atherosclerotic Calcification and Smooth Muscle Cell Osteogenic Differentiation","volume":"37","author":"McRobb","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib672","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1161\/ATVBAHA.115.306102","article-title":"Estrogen-Related Receptor \u03b3 Plays a Key Role in Vascular Calcification Through the Upregulation of BMP2 Expression","volume":"35","author":"Kim","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib673","article-title":"Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib674","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/ATVBAHA.119.313366","article-title":"Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects","volume":"40","author":"Rogers","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib675","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.124.071954","article-title":"Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning","volume":"151","author":"Rosa","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib676","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/ATVBAHA.108.174128","article-title":"Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis","volume":"28","author":"Preusch","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib677","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/DMSO.S4170","article-title":"Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes","volume":"2","author":"Desouza","year":"2009","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.isci.2025.114042_bib678","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2337\/db07-0765","article-title":"Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism","volume":"57","author":"Biscetti","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.isci.2025.114042_bib679","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000143793","article-title":"Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation","volume":"46","author":"Biscetti","year":"2009","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib680","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032345","article-title":"Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease","volume":"24","author":"Wagner","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib681","first-page":"693","article-title":"Loss of PPAR\u03b3 in endothelial cells leads to impaired angiogenesis","volume":"129","author":"Vattulainen-Collanus","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.isci.2025.114042_bib682","doi-asserted-by":"crossref","first-page":"13503","DOI":"10.1074\/jbc.M510357200","article-title":"Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells","volume":"281","author":"Kim","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114042_bib683","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/cvr\/cvp400","article-title":"PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium","volume":"86","author":"Scoditti","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib684","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11010-011-0989-9","article-title":"Anti-angiogenic action of PPAR\u03b3 ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation","volume":"358","author":"Kim","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.isci.2025.114042_bib685","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.ATV.0000250972.83623.61","article-title":"Activation of PPARbeta\/delta induces endothelial cell proliferation and angiogenesis","volume":"27","author":"Piqueras","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib686","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1152\/ajpendo.00581.2007","article-title":"Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle","volume":"295","author":"Gaudel","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib687","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cvr\/cvp106","article-title":"Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin","volume":"83","author":"Wagner","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib688","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2012-07-443903","article-title":"The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3\/Nur77 and subsequently truncate it through thrombospondin-1","volume":"121","author":"Qin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114042_bib689","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.20051523","article-title":"Orphan nuclear receptor TR3\/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity","volume":"203","author":"Zeng","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2025.114042_bib690","doi-asserted-by":"crossref","first-page":"12066","DOI":"10.1073\/pnas.1018438108","article-title":"Orphan nuclear transcription factor TR3\/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib691","doi-asserted-by":"crossref","DOI":"10.4172\/2324-9110.1000184","article-title":"Orphan Nuclear Receptor TR3\/Nur77 is a Specific Therapeutic Target for Hepatic Cancers","volume":"6","author":"Zeng","year":"2017","journal-title":"J. Clin. Exp. Oncol."},{"key":"10.1016\/j.isci.2025.114042_bib692","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.589770","article-title":"Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis","volume":"9","author":"Crean","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2025.114042_bib693","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mvr.2018.10.011","article-title":"Orphan nuclear receptor TR3\/Nur77 differentially regulates the expression of integrins in angiogenesis","volume":"122","author":"Ye","year":"2019","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib694","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mvr.2019.03.006","article-title":"DLL4 and Jagged1 are angiogenic targets of orphan nuclear receptor TR3\/Nur77","volume":"124","author":"Peng","year":"2019","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.isci.2025.114042_bib695","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12951-024-02357-z","article-title":"Promoting collateral formation in type 2 diabetes mellitus using ultra-small nanodots with autophagy activation and ROS scavenging","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.isci.2025.114042_bib696","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118727","article-title":"NR4A3 induces endothelial dysfunction through up-regulation of endothelial 1 expression in adipose tissue-derived stromal cells","volume":"264","author":"Wang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.isci.2025.114042_bib697","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.atherosclerosis.2005.04.008","article-title":"NOR-1 is involved in VEGF-induced endothelial cell growth","volume":"184","author":"Rius","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.isci.2025.114042_bib698","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCRESAHA.112.266478","article-title":"Revascularization of ischemic skeletal muscle by estrogen-related receptor-\u03b3","volume":"110","author":"Matsakas","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib699","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001794RR","article-title":"Estrogen-related receptor alpha is involved in angiogenesis and skeletal muscle revascularization in hindlimb ischemia","volume":"35","author":"Sopariwala","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.isci.2025.114042_bib700","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00411-18","article-title":"Loss of Estrogen-Related Receptor Alpha Facilitates Angiogenesis in Endothelial Cells","volume":"39","author":"Likhite","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.114042_bib701","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1161\/01.RES.88.4.e38","article-title":"Retinoids induce fibroblast growth factor-2 production in endothelial cells via retinoic acid receptor alpha activation and stimulate angiogenesis in vitro and in vivo","volume":"88","author":"Gaetano","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.isci.2025.114042_bib702","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10456-021-09773-x","article-title":"Loss of endothelial glucocorticoid receptor promotes angiogenesis via upregulation of Wnt\/\u03b2-catenin pathway","volume":"24","author":"Liu","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.isci.2025.114042_bib703","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/path.5269","article-title":"Mineralocorticoid receptor negatively regulates angiogenesis through repression of STAT3 activity in endothelial cells","volume":"248","author":"Zheng","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.isci.2025.114042_bib704","doi-asserted-by":"crossref","first-page":"10401","DOI":"10.1073\/pnas.1504387112","article-title":"Nuclear receptor ROR\u03b1 regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation","volume":"112","author":"Sun","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib705","doi-asserted-by":"crossref","first-page":"H1955","DOI":"10.1152\/ajpheart.00306.2007","article-title":"Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries","volume":"293","author":"Eid","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib706","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106690","article-title":"Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP\/Epac\/JNK\/AP-1 pathway and potentiates cold-induced vasoconstriction","volume":"131","author":"Fardoun","year":"2020","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib707","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0000000000001489","article-title":"GPER Acts Through the cAMP\/Epac\/JNK\/AP-1 Pathway to Induce Transcription of Alpha 2C Adrenoceptor in Human Microvascular Smooth Muscle Cells","volume":"82","author":"Fardoun","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib708","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1061374","article-title":"G protein estrogen receptor as a potential therapeutic target in Raynaud's phenomenon","volume":"13","author":"Fardoun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib709","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.isci.2025.114042_bib710","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbadis.2011.04.005","article-title":"Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-\u03baB signaling in the intestine","volume":"1812","author":"Gadaleta","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.isci.2025.114042_bib711","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1756-0500-5-461","article-title":"Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease","volume":"5","author":"Attinkara","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.isci.2025.114042_bib712","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/ibd\/izy092","article-title":"Ancient Nuclear Receptor VDR With New Functions: Microbiome and Inflammation","volume":"24","author":"Bakke","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.isci.2025.114042_bib713","first-page":"97","article-title":"Lack of Vitamin D Receptor Leads to Hyperfunction of Claudin-2 in Intestinal Inflammatory Responses","volume":"25","author":"Zhang","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.isci.2025.114042_bib714","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00274.2010","article-title":"Estrogen receptor-\u03b2 signaling modulates epithelial barrier function","volume":"300","author":"Looijer-van Langen","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.isci.2025.114042_bib715","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tips.2016.10.006","article-title":"Estrogen Receptor \u03b2 as a Pharmaceutical Target","volume":"38","author":"Warner","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib716","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1002\/ijc.32037","article-title":"Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity","volume":"144","author":"Ibrahim","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2025.114042_bib717","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029756","article-title":"Selective non-steroidal glucocorticoid receptor agonists attenuate inflammation but do not impair intestinal epithelial cell restitution in vitro","volume":"7","author":"Reuter","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib718","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3389\/fimmu.2019.01070","article-title":"Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD","volume":"10","author":"Klepsch","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib719","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41401-024-01315-7","article-title":"Liver X receptor inverse agonist SR9243 attenuates rheumatoid arthritis via modulating glycolytic metabolism of macrophages","volume":"45","author":"Zheng","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2025.114042_bib720","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14298","article-title":"Synovial expression of glucocorticoid receptor parallels fibroblast activation in patients with rheumatoid arthritis","volume":"54","author":"Vlachogiannis","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.isci.2025.114042_bib721","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/en.2017-00728","article-title":"Glucocorticoid Signaling in Health and Disease: Insights From Tissue-Specific GR Knockout Mice","volume":"159","author":"Whirledge","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib722","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1007\/s10067-020-05143-y","article-title":"Vitamin D receptor (VDR) gene polymorphism and risk of rheumatoid arthritis (RA): systematic review and meta-analysis","volume":"39","author":"Bagheri-Hosseinabadi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.isci.2025.114042_bib723","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/ard.2010.142331","article-title":"Vitamin D receptor regulates TNF-mediated arthritis","volume":"70","author":"Zwerina","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2025.114042_bib724","article-title":"Identification of PPARG as key gene to link coronary atherosclerosis disease and rheumatoid arthritis via microarray data analysis","volume":"19","author":"Zhang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114042_bib725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103214","article-title":"PPARG-mediated autophagy activation alleviates inflammation in rheumatoid arthritis","volume":"146","author":"Geng","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.isci.2025.114042_bib726","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.835697","article-title":"Orphan Nuclear Receptor NR4A2 Is Constitutively Expressed in Cartilage and Upregulated in Inflamed Synovium From hTNF-Alpha Transgenic Mice","volume":"13","author":"Lilley","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib727","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/art.34399","article-title":"Orphan nuclear receptor NR4A2 induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription","volume":"64","author":"Mix","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2025.114042_bib728","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/rheumatology\/ken368","article-title":"Estrogen receptor-related receptor-alpha (ERR-alpha) is dysregulated in inflammatory arthritis","volume":"47","author":"Bonnelye","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.isci.2025.114042_bib729","doi-asserted-by":"crossref","first-page":"13249","DOI":"10.1021\/acsnano.4c02420","article-title":"Dexamethasone-Integrated Mesenchymal Stem Cells for Systemic Lupus Erythematosus Treatment via Multiple Immunomodulatory Mechanisms","volume":"18","author":"Ma","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.isci.2025.114042_bib730","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106365","article-title":"Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-\u03b1","volume":"83","author":"Huang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib731","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41392-021-00867-y","article-title":"Neuronal NR4A1 deficiency drives complement-coordinated synaptic stripping by microglia in a mouse model of lupus","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib732","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10067-007-0568-3","article-title":"Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"26","author":"Inui","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.isci.2025.114042_bib733","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116417","article-title":"Vitamin D and systemic lupus erythematosus: Causality and association with disease activity and therapeutics","volume":"227","author":"Ho","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib734","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0961203320909432","article-title":"Associations of four common VDR polymorphisms with rheumatoid arthritis and systemic lupus erythematosus: evidence from a meta-analysis","volume":"29","author":"Zhang","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.isci.2025.114042_bib735","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713379","article-title":"Vitamin D Receptor Gene Polymorphism Predicts the Outcome of Multidisciplinary Rehabilitation in Multiple Sclerosis Patients","volume":"24","author":"Guerini","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib736","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.1111\/jcmm.15928","article-title":"Methylprednisolone alleviates multiple sclerosis by expanding myeloid-derived suppressor cells via glucocorticoid receptor \u03b2 and S100A8\/9 up-regulation","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.isci.2025.114042_bib737","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111333","article-title":"Role of liver X receptor in multiple sclerosis: A long furtive life behind a barrier","volume":"224","author":"Abulaban","year":"2025","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.isci.2025.114042_bib738","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1073\/pnas.1424951112","article-title":"Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum","volume":"112","author":"Meffre","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib739","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.neuron.2016.04.039","article-title":"Nuclear Receptor NR1H3 in Familial Multiple Sclerosis","volume":"90","author":"Wang","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.isci.2025.114042_bib740","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1083\/jcb.201505119","article-title":"Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation","volume":"211","author":"de la Fuente","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.isci.2025.114042_bib741","first-page":"329","article-title":"Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation","volume":"59","author":"Huang","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.isci.2025.114042_bib742","doi-asserted-by":"crossref","first-page":"18061","DOI":"10.1073\/pnas.1411294111","article-title":"Multiple functional therapeutic effects of the estrogen receptor \u03b2 agonist indazole-Cl in a mouse model of multiple sclerosis","volume":"111","author":"Moore","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114042_bib743","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(15)00322-1","article-title":"Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Voskuhl","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2025.114042_bib744","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40001-024-01700-2","article-title":"Role of fenofibrate in multiple sclerosis","volume":"29","author":"Abulaban","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.isci.2025.114042_bib745","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177692","article-title":"The NR4A2\/VGF pathway fuels inflammation-induced neurodegeneration via promoting neuronal glycolysis","volume":"134","author":"Woo","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib746","first-page":"371","article-title":"Update on Clinical Trials for Nonalcoholic Steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib747","first-page":"3446174","article-title":"Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations","volume":"22","author":"Issa","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.isci.2025.114042_bib748","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jocd.13340","article-title":"Selective RAR agonists for acne vulgaris: A narrative review","volume":"19","author":"Kassir","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.isci.2025.114042_bib749","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111688","article-title":"MASLD\/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists","volume":"212","author":"Cooreman","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.isci.2025.114042_bib750","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018812053","article-title":"PPAR\u03b2\/\u03b4 a potential target in pulmonary hypertension blighted by cancer risk","volume":"9","author":"Mitchell","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.isci.2025.114042_bib751","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib752","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jare.2023.08.006","article-title":"Forsythiaside A alleviates acute lung injury by inhibiting inflammation and epithelial barrier damages in lung and colon through PPAR-\u03b3\/RXR-\u03b1 complex","volume":"60","author":"Wang","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.isci.2025.114042_bib753","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114978","article-title":"1,8-Cineole ameliorates diabetic retinopathy by inhibiting retinal pigment epithelium ferroptosis via PPAR-\u03b3\/TXNIP pathways","volume":"164","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2025.114042_bib754","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108778","article-title":"Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease","volume":"113","author":"Ni","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2025.114042_bib755","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopha.2018.05.135","article-title":"Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice","volume":"105","author":"Yan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2025.114042_bib756","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/ptr.6743","article-title":"Extract of Schisandra chinensis fruit protects against metabolic dysfunction in high-fat diet induced obese mice via FXR activation","volume":"34","author":"Gu","year":"2020","journal-title":"Phytother Res."},{"key":"10.1016\/j.isci.2025.114042_bib757","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2025.114042_bib758","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40265-023-01978-2","article-title":"Correction: Elacestrant: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.114042_bib759","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mce.2017.07.017","article-title":"Selective ER-\u03b1 agonist alleviates vascular endothelial dysfunction in ovariectomized type 2 diabetic rats","volume":"460","author":"Bansal","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib760","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ggi.15032","article-title":"Astragaloside IV inhibits vascular calcification through estrogen receptor alpha","volume":"25","author":"Nanao-Hamai","year":"2025","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.isci.2025.114042_bib761","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1093\/rheumatology\/keab347","article-title":"Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly","volume":"60","author":"Ruiz-Irastorza","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.isci.2025.114042_bib762","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/02770903.2022.2155189","article-title":"Dexamethasone versus prednisone\/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis","volume":"60","author":"Dahan","year":"2023","journal-title":"J. Asthma"},{"key":"10.1016\/j.isci.2025.114042_bib763","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/25785826.2024.2422180","article-title":"Autonomic disorder in systemic lupus erythematosus: autoimmune autonomic ganglionopathy","volume":"47","author":"Azuma","year":"2024","journal-title":"Immunol. Med."},{"key":"10.1016\/j.isci.2025.114042_bib764","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","article-title":"A General Introduction to Glucocorticoid Biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114042_bib765","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.isci.2025.114042_bib766","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104802","article-title":"Natural and synthetic compounds as dissociated agonists of glucocorticoid receptor","volume":"156","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2025.114042_bib767","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib768","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.4655","article-title":"Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial","volume":"37","author":"Pignolo","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.isci.2025.114042_bib769","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.isci.2025.114042_bib770","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.isci.2025.114042_bib771","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib772","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2025.114042_bib773","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114042_bib774","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09031936.00161911","article-title":"Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor","volume":"40","author":"Stolk","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2025.114042_bib775","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1038\/s41467-023-43175-5","article-title":"Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis","volume":"14","author":"Fang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114042_bib776","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1158\/1078-0432.CCR-17-3028","article-title":"Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial","volume":"24","author":"Neven","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114042_bib777","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR Ligands: Current Status and Clinical Applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib778","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2025.114042_bib779","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jconrel.2020.11.016","article-title":"Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport","volume":"329","author":"Yuan","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.isci.2025.114042_bib780","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/646423","article-title":"Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention","volume":"2015","author":"Horita","year":"2015","journal-title":"PPAR Res."},{"key":"10.1016\/j.isci.2025.114042_bib781","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.isci.2025.114042_bib782","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3803\/EnM.2020.659","article-title":"Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study","volume":"35","author":"Koh","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib783","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2025.114042_bib784","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3803\/EnM.2021.1021","article-title":"Update on Glucocorticoid Induced Osteoporosis","volume":"36","author":"Cho","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002024","article-title":"Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study","volume":"13","author":"Fardet","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2025.114042_bib786","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","article-title":"Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know","volume":"99","author":"Tavares","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.isci.2025.114042_bib787","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clinthera.2023.11.013","article-title":"The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes","volume":"46","author":"Limbachia","year":"2024","journal-title":"Clin. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib788","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2025.114042_bib789","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2147\/OPTH.S442749","article-title":"Glucocorticoid-Induced Ocular Hypertension and Glaucoma","volume":"18","author":"Harvey","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.isci.2025.114042_bib790","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/CCID.S224211","article-title":"Glucocorticoid-Induced Skin Atrophy: The Old and the New","volume":"13","author":"Niculet","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.isci.2025.114042_bib791","doi-asserted-by":"crossref","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","article-title":"Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis","volume":"109","author":"Koning","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib792","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2025.114042_bib793","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114042_bib794","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2025.114042_bib795","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.isci.2025.114042_bib796","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114042_bib797","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1210\/en.2005-0706","article-title":"Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis","volume":"147","author":"Sharma","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.isci.2025.114042_bib798","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jc.2006-0696","article-title":"Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects","volume":"92","author":"Golden","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.isci.2025.114042_bib799","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.isci.2025.114042_bib800","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.isci.2025.114042_bib801","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.isci.2025.114042_bib802","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jcph.1996","article-title":"Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment","volume":"62","author":"Chen","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib803","doi-asserted-by":"crossref","first-page":"582S","DOI":"10.1093\/ajcn\/88.2.582S","article-title":"Pharmacokinetics of vitamin D toxicity","volume":"88","author":"Jones","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.isci.2025.114042_bib804","series-title":"Endotext","article-title":"Vitamin D: Production, Metabolism, and Mechanism of Action","author":"Bikle","year":"2000"},{"key":"10.1016\/j.isci.2025.114042_bib805","doi-asserted-by":"crossref","DOI":"10.3390\/nu10121890","article-title":"The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD","volume":"10","author":"Lu","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.isci.2025.114042_bib806","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.isci.2025.114042_bib807","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13058-017-0916-4","article-title":"Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients","volume":"19","author":"Helland","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.isci.2025.114042_bib808","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fphar.2017.00582","article-title":"Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen","volume":"8","author":"Schroth","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib809","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment","volume":"80","author":"Borges","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib810","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.isci.2025.114042_bib811","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.122.000858","article-title":"Regulation of Nuclear Receptors PXR and CAR by Small Molecules and Signal Crosstalk: Roles in Drug Metabolism and Beyond","volume":"51","author":"Poudel","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.isci.2025.114042_bib812","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1038\/s41598-021-85174-w","article-title":"Enteric reabsorption processes and their impact on drug pharmacokinetics","volume":"11","author":"Ibarra","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114042_bib813","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mce.2010.06.018","article-title":"What are nuclear receptor ligands?","volume":"334","author":"Sladek","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.isci.2025.114042_bib814","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41392-025-02270-3","article-title":"Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions","volume":"10","author":"Jin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib815","series-title":"StatPearls","article-title":"Drug Distribution","author":"Onetto","year":"2025"},{"key":"10.1016\/j.isci.2025.114042_bib816","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cpt.3506","article-title":"Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions","volume":"117","author":"Cilliers","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114042_bib817","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/psp4.12699","article-title":"Perspective on model-informed drug development","volume":"10","author":"Lesko","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2025.114042_bib818","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1147699","article-title":"Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review","volume":"10","author":"Yang","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.isci.2025.114042_bib819","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29092022","article-title":"Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights","volume":"29","author":"Morrison","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.isci.2025.114042_bib820","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422502303X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422502303X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:29:36Z","timestamp":1783474176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422502303X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":820,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S258900422502303X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114042","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114042"}}